



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
WO 03/080125 A2(51) International Patent Classification<sup>7</sup>: A61K 313/4184

[GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(21) International Application Number: PCT/GB03/01210

(74) Agent: GIDDINGS, Peter, John; GlaxoSmithKline, 980 Great West Road CN925.1, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 21 March 2003 (21.03.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:  
0206861.7 22 March 2002 (22.03.2002) GB(71) Applicant (*for all designated States except US*): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and






(75) Inventors/Applicants (*for US only*): ALBERTI, Michael, John [US/US]; GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 (US). GARLAND, Stephen [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). JUNG, David, Kendall [US/US]; GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 (US). VEAL, James, Marvin [US/US]; c/o GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 (US). WITHERINGTON, Jason

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MEDICAMENTS



(57) Abstract: A method of treating an Msk-1 and/or ROCK(1 and 2) mediated disease or condition in a mammal comprising administration of an effective amount of a compounds of the formula (I) and physiologically acceptable salts thereof wherein, R<sub>1</sub> is a 5, or 6 membered heterocyclic group selected from group a, b, c or d wherein X<sub>1</sub> is a group selected from N or CR<sub>7</sub> and X<sub>2</sub> is a group selected from O, S or NR<sub>8</sub>; X<sub>3</sub> and X<sub>4</sub> which may be the same or different is a group selected from N or CR<sub>7</sub>; X<sub>5</sub> is a group selected from O, S or NR<sub>8</sub> and X<sub>6</sub> is N or CR<sub>7</sub>; X<sub>7</sub>, X<sub>8</sub> and X<sub>9</sub> may be the same or different and selected from a group N or CR<sub>7</sub>, pharmaceutical compositions, novel compounds and processes for their preparation.

## Medicaments

- The present invention relates to the use of kinase inhibitors in the treatment of disease, to pharmaceutical compositions for use therein, to novel compounds and to processes for their preparation. More particularly the present invention relates to the use of benzimidazole derivatives which are inhibitors of the kinases mitogen and stress activated protein kinase-1 (herein after referred to as Msk-1) and/or Rho-kinase (hereinafter referred to as ROCK 1 and 2 ) in the treatment or prophylaxis of diseases and/or conditions mediated through the kinases Msk-1 and/or ROCK 1 and/or 2.
- An important mechanism by which cells sense and respond to extracellular stimuli is the activation and modulation of intracellular signal transduction pathways. One of the major signal transduction systems utilized by cells is the MAPK signalling pathways. These pathways share a common architecture, consisting of a cascade of protein kinases that are sequentially phosphorylated and activated, resulting in the activation of a MAP kinase (MAPK). Three MAP kinase pathways have been widely characterised: the Erk pathway, which responds to mitogenic stimuli and results in activation of Erk, and the JNK and p38 pathways, which are commonly associated with transducing cellular stress signals and result in activation of JNK and p38 MAPK.
- Mitogen and stress-activated protein kinases 1 (Msk1) and 2 (Msk2, also named RSKB or RLPK) constitute a family of kinases that can be phosphorylated and activated by either p38 or Erk. Msks are reported to be localized exclusively to the nucleus, and are responsible for the phosphorylation and activation of the transcription factor CREB in response to certain stress stimuli. In macrophage and monocyte cells, Msk1 is involved in CREB-mediated transcriptional regulation of IL-1 $\beta$  and Cox2 in response to bacterial lipopolysaccharide. In addition, Msk1 can also phosphorylate the nucleosomal proteins histone H3 and HMG14, and thus may have a critical role in linking cellular signalling pathways to chromatin modification and modulation of transcription factor complexes.

Inhibitors of kinases in the Erk MAPK cascade have been suggested for use in the treatment and/or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events, including cerebral ischemia after cardiac arrest, stroke and multi-infarct dementia and also after cerebral ischemic events such as those  
5 resulting from head injury, surgery and/or during childbirth. Since Msks are activated by Erk MAPK, Msk inhibitors could serve a similar use. Although Msks are only one of a number of Erk substrates, CREB is involved in many different transcriptional activities, and Msk-mediated CREB phosphorylation could play a role in some cancers. In addition, through modulation of production of pro-inflammatory cytokines such as IL-1 $\beta$  and  
10 prostaglandins, inhibitors of Msks could be of use in treatments for neuroinflammatory diseases such as stroke, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and inflammatory pain, as well as other inflammatory diseases such as rheumatoid arthritis, irritable bowel syndrome, inflammatory bowel disease and asthma.

15 Another of the major signal transduction systems utilized by cells is the RhoA-signalling pathways. RhoA is a small GTP binding protein that can be activated by several extracellular stimuli such as growth factor, hormones, mechanic stress, osmotic change as well as high concentration of metabolites like glucose. RhoA activation involves GTP binding, conformation alteration, post-translational modification  
20 (geranylgeranyllization and farnesylation) and activation of its intrinsic GTPase activity. Activated RhoA is capable of interacting with several effector proteins including ROCKs and transmit signals into cellular cytoplasm and nucleus.

ROCK1 and 2 constitute a family of kinases that can be activated by RhoA-GTP complex via physical association. Activated ROCKs phosphorylate a number of  
25 substrates and play important roles in pivotal cellular functions. The substrates for ROCKs include myosin binding subunit of myosin light chain phosphatase (MBS, also named MYPT1), adducin, moesin, myosin light chain (MLC), LIM kinase as well as

transcription factor FHL. The phosphorylation of these substrates modulate the biological activity of the proteins and thus provide a means to alter cell's response to external stimuli. One well documented example is the participation of ROCK in smooth muscle contraction. Upon stimulation by phenylephrine, smooth muscle from blood vessels contracts. Studies have shown that phenylephrine stimulates  $\beta$ -adrenergic receptors and leads to the activation of RhoA. Activated RhoA in turn stimulates kinase activity of ROCK1 and which in turn phosphorylates MBS. Such phosphorylation inhibits the enzyme activity of myosin light chain phosphatase and increases the phosphorylation of myosin light chain itself by a calcium-dependent myosin light chain kinase (MLCK) and consequently increases the contractility of myosin-actin bundle, leading to smooth muscle contraction. This phenomena is also sometimes called calcium sensitization. In addition to smooth muscle contraction, ROCKs have also been shown to be involved in cellular functions including apoptosis, cell migration, transcriptional activation, fibrosis, cytokinesis, inflammation and cell proliferation. Moreover, in neurons ROCK plays a critical role in the inhibition of axonal growth by myelin-associated inhibitory factors such as myelin-associated glycoprotein (MAG). ROCK-activity also mediates the collapse of growth cones in developing neurons. Both processes are thought to be mediated by ROCK-induced phosphorylation of substrates such as LIM kinase and myosin light chain phosphatase, resulting in increased contractility of the neuronal actin-myosin system.

Inhibitors of ROCKs have been suggested for use in the treatments of a variety of diseases. They include cardiovascular diseases such as hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure and atherosclerosis. In addition, because of its muscle relaxing properties, it is also suitable for asthma, female sexual dysfunction, male erectile dysfunctions and over-active bladder syndrome. ROCK inhibitors have been shown to possess anti-inflammatory properties. Thus they can be used as treatment for neuroinflammatory diseases such as


stroke, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and inflammatory pain, as well as other inflammatory diseases such as rheumatoid arthritis, irritable bowel syndrome, inflammatory bowel disease. In addition, based on their neurite outgrowth inducing effects, ROCK inhibitors could be useful drugs for neuronal regeneration, inducing new axonal growth and axonal rewiring across lesions within the CNS. ROCK inhibitors are therefore likely to be useful for regenerative (recovery) treatment of CNS disorders such as spinal cord injury, acute neuronal injury (stroke, traumatic brain injury), Parkinson's disease, Alzheimer's disease and other neurodegenerative disorders. Since ROCK inhibitors reduce cell proliferation and cell migration, they could be useful in treating cancer and tumor metastasis. Furthermore, there is evidence suggesting that ROCK inhibitors suppress cytoskeletal rearrangement upon virus invasion, thus they also have potential therapeutic value in anti-viral and anti-bacterial applications. ROCK inhibitors are also useful for the treatment of insulin resistance and diabetes.

15

WO 97/12615 teaches *inter alia* novel 2-heteroaryl benzimidazole derivatives, which are inhibitors of the specific lipoxygenase enzyme 15-LO.

20 We have now identified a group of benzimidazole derivatives which are potent inhibitors of the protein kinases Msk-1 and/or ROCK(1 and/or 2).


The present invention thus provides a method of treating an Msk-1 and/or ROCK(1 and 2) mediated disease or condition in a mammal comprising administration of an effective amount of a compound of the general formula (I)



(I)

and physiologically acceptable salts thereof wherein,

R<sub>1</sub> is a 5, or 6 membered heterocyclic group selected from group a, b, c or d




(a)

5


wherein X<sub>1</sub> is a group selected from N or CR<sub>7</sub> and X<sub>2</sub> is a group selected from O, S or

NR<sub>8</sub>;




(b)

10 wherein X<sub>3</sub> and X<sub>4</sub> which may be the same or different is a group selected from N or CR<sub>7</sub>;



(c)

wherein X<sub>5</sub> is a group selected from O, S or NR<sub>8</sub> and X<sub>6</sub> is N or CR<sub>7</sub>;



wherein  $X_7$ ,  $X_8$  and  $X_9$  may be the same or different and selected from a group N or  $CR_7$

$R_2$  and  $R_8$  independently represents hydrogen, hydroxy, aryl, heteroaryl,  $C_{3-7}$ cycloalkyl, heterocyclyl, a group  $YR_9$ ,  $N=R_{10}$ ,  $CONR_{11}R_{12}$ ,  $COCH_2NR_{11}R_{12}$ ,  $NR_{11}COR_{13}$ ,

- 5  $SO_2NR_{11}R_{12}$  or  $C_{1-6}$ alkyl [optionally substituted by a group selected from optionally substituted phenyl,  $C_{3-7}$ cycloalkyl, heteroaryl, heterocyclyl, acylamino,  $NH_2$ ,  $R_{16}NH$ ,  $R_{16}R_{17}N$ ,  $SO_2NR_{11}R_{12}$ ,  $CONR_{11}R_{12}$ ,  $NHCOR_{13}$ ,  $OalkNR_{16}R_{17}$ ,  $SalkNR_{16}R_{17}$  or  $NR_{14}SO_2R_{15}$  group]; or  $R_2$  and  $R_3$  together form a  $C_{2-4}$  alkylene chain.

$R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  independently represent a group selected from hydrogen, halogen,

- 10 hydroxy,  $R_{16}O$ ,  $R_{16}S(O)_n$ ,  $NH_2$ ,  $R_{16}NH$ ,  $R_{16}R_{17}N$ , nitro, formyl,  $C_{1-4}$ alkanoyl, alkenyl (optionally substituted by optionally substituted phenyl, heterocyclyl, or heteroaryl), carboxy, optionally substituted phenyl, heteroaryl, cycloalkyl, cycloalkylalkyl, aryloxy, heteroaryloxy, heterocyclyl,  $CONR_{11}R_{12}$ ,  $NR_{11}COR_{13}$ ,  $SO_2NR_{11}R_{12}$ ,  $NR_{14}SO_2R_{15}$  or  $C_{1-6}$ alkyl [optionally substituted by a group selected from optionally substituted phenyl,  $C_{3-7}$ cycloalkyl, heteroaryl, heterocyclyl,  $NH_2$ ,  $R_{16}NH$ ,  $R_{16}R_{17}N$ , acylamino, hydroxy,  $CONR_{11}R_{12}$ ,  $NR_{11}COR_{13}$ ,  $SO_2NR_{11}R_{12}$ ,  $NR_{14}SO_2R_{15}$ ,  $OalkNR_{16}R_{17}$ , or  $SalkNR_{16}R_{17}$  group];

$Y$  represents O,  $NH$ ,  $NR_9$  or  $S(O)_n$ ;

$R_9$  represents aryl, heteroaryl, cycloalkyl, heterocyclyl or  $C_{1-6}$ alkyl [optionally substituted

- 20 by a group selected from optionally substituted phenyl,  $C_{3-7}$ cycloalkyl, heteroaryl, heterocyclyl,  $NH_2$ ,  $R_{16}NH$ ,  $R_{16}R_{17}N$ , acylamino, hydroxy,  $CONR_{11}R_{12}$ ,  $NR_{11}COR_{13}$ ,  $SO_2NR_{11}R_{12}$ ,  $NR_{14}SO_2R_{15}$ ,  $OalkNR_{16}R_{17}$ , or  $SalkNR_{16}R_{17}$  group];

R<sub>10</sub> represents an alkylidene group which may be substituted by an aryl, heteroaryl, heterocyclyl or cycloalkyl group or R<sub>10</sub> represents a cycloalkylidene or heterocycloalkylidene group.

R<sub>11</sub> and R<sub>12</sub> independently represent hydrogen, aryl, heteroaryl, cycloalkyl or C<sub>1-6</sub>alkyl [optionally substituted by a group selected from optionally substituted phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl, heterocyclyl, NH<sub>2</sub>, R<sub>16</sub>NH, R<sub>16</sub>R<sub>17</sub>N, or acylamino group] or R<sub>11</sub> and R<sub>12</sub> together with the nitrogen atom to which they are attached form a 4-7 heterocyclic ring which may be saturated or unsaturated and optionally contains another heteroatom selected from O, N or S(O)<sub>n</sub>;

R<sub>13</sub> and R<sub>15</sub> independently represent, aryl, heteroaryl, heterocyclyl, cycloalkyl or C<sub>1-6</sub>alkyl [optionally substituted by a group selected from optionally substituted phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl, heterocyclyl, NH<sub>2</sub>, R<sub>16</sub>NH, R<sub>16</sub>R<sub>17</sub>N, or acylamino group] or the group NR<sub>11</sub>R<sub>12</sub> wherein R<sub>11</sub> and R<sub>12</sub> have the meanings defined above;

R<sub>14</sub> represents hydrogen, aryl, heteroaryl, heterocyclyl, cycloalkyl or C<sub>1-6</sub>alkyl [optionally substituted by a group selected from optionally substituted phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl, heterocyclyl, NH<sub>2</sub>, R<sub>16</sub>NH, R<sub>16</sub>R<sub>17</sub>N, or acylamino group]; R<sub>16</sub> and R<sub>17</sub> independently represent a group selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

Alk is a C<sub>2-4</sub> straight or branched alkylene chain

n is zero, 1 or 2.

It will be appreciated that any of the substituents R<sub>1</sub> to R<sub>17</sub> as defined in formula (1) above may contain at least one asymmetric center and it is to be understood that the invention includes all possible enantiomers arising there from and mixtures thereof including racemates.



The term alkyl as a group or part of a group e.g. alkoxy, alkylthio, alkylamino, dialkylamino, optionally substituted alkyl e.g. aminoalkyl, cycloalkylalkyl, aralkyl, heteroarylalkyl or heterocyclalkyl refers to a C<sub>1-6</sub> straight or branched chain alkyl group.

The term halogen includes fluorine, chlorine, bromine or iodine.

- 5        The term aryl as a group or part of a group e.g. aryloxy, aralkyl or arylamino refers to an optionally substituted phenyl or fused bicyclic aryl group e.g. naphthyl.
- The terms aryl, optionally substituted phenyl, heteroaryl, C<sub>3-7</sub> cycloalkyl as a group or part of a group and 4-7 membered heterocycl as a group or part of a group includes such groups which are optionally substituted with 1 to 3 substituents which may be the
- 10    same or different and selected from halogen, aryl, heteroaryl, heterocyclalkyl, hydroxy, alkyl, alkoxy, trifluoroalkyl, amino, alkylamino, dialkylamino, arylamino, heteroarylamino, heterocyclamino, acylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, arylaminoalkyl, heteroarylaminoalkyl, cycloalkylaminoalkyl, heterocyclaminoalkyl, hydroxyalkyl, CONR<sub>11</sub>R<sub>12</sub>, CH<sub>2</sub>CONR<sub>11</sub>R<sub>12</sub> carboxy, carboxamido,
- 15    alkoxycarbonyl, aminoalkoxy, dialkylaminoalkoxy, acylaminoalkoxy, sulphonamido, aminosulphonyl, cyano, formyl, nitro, R<sub>18</sub>O or R<sub>18</sub>S(O)<sub>n</sub> wherein R<sub>18</sub> is a group selected from alkyl, aryl, heteroaryl or heterocyclalkoxy and n is zero, one or two, or each of the said groups form part of a fused bicyclic ring system containing up to 10 ring members and which is at least partially saturated.
- 20    The term heteroaryl as a group or part of a group e.g. heteroaryloxy refers to a 5 or 6 membered ring or a fused 5,6 or 6,6 bicyclic ring system.

When heteroaryl represents a 5 membered group it contains a heteroatom selected from O, N or S and may optionally contain a further 1 to 3 nitrogen atoms. Examples of such groups include furanyl, thienyl, isoxazolyl, oxazolyl or imidazolyl.

- 25    When heteroaryl represents a 6-membered group it contains from 1 to 3 nitrogen atoms. Examples of such groups include pyridyl, pyrimidinyl, or triazinyl.

The term 5,6 fused bicyclic heteroaryl group refers to a group in which the 5-membered ring contains an oxygen, sulphur or NH group and the 6 membered ring optionally contains from 1 to 3 nitrogen atoms. Examples of such groups include benzofuranyl, benzothieryl or indolyl.

5           The term 6,6-fused bicyclic heteroaryl group refers to a bicyclic heteroaryl group which contains at least one nitrogen atom in one of the rings and may contain up to 3 nitrogen atoms in each ring. Examples of such groups include quinoliny, isoquinoliny or naphthyridiny also the term 6,6 fused bicyclic heteroaryl group refers to a 6-membered heteroaryl group which is fused to a partially saturated carbocyclic group. Examples of  
10   such a group includes tetrahydroquinoliny or tetrahydroisoquinoliny.

The term heterocyclyl as a group or part of a group e.g. heterocyclylalkyl or heterocyclylalkylidene refers to a 4-7 membered heterocyclyl group which is linked to the rest of the compound of formula (1) via a carbon or nitrogen atom in that group and which contains one or two hetero atoms selected from N, O or S(O)<sub>n</sub>, and when the  
15   heterocyclyl group contains a ring member NH or the heterocyclyl group is substituted by a primary or secondary amino group then the term also includes N-alkyl, N-optionally substituted phenyl, N-benzyl or, N-acyl derivatives thereof. Examples of such heterocyclic groups include optionally substituted pyrrolidine, piperidine, piperazine homopiperazine, morpholine or thiomorpholine.

20

The term cycloalkyl as a group or part of a group e.g. cycloalkylalkyl or cycloalkylidene refers to a 3-7 membered carbocyclic group.

The term fused bicyclic ring system containing up to 10 ring members and which is at least partially saturated includes carbocyclic and heterocyclic 6,5 and 6,6 bicyclic  
25   ring systems. Examples of such 6,5 and 6,6 carbocyclic ring systems include those wherein the bicyclic ring comprises a benzene ring fused to a 5- or 6-membered carbocyclic ring which is at least partially saturated e.g. tetrahydronaphthyl, indanyl or

indenyl. Examples of such 6,5, or 6,6 heterocyclic rings include those wherein one ring is benzene which is fused to a 5 or 6 membered ring containing one or two hetero atoms selected from O, S or N e.g. indolyl, isoindolyl, 2,3-dihydro-1H-isoindol-5-yl, dihydrobenzofuranyl, dihydrobenzothieryl, 1,3-benzodioxolyl, benzopyrrolyl, 1,3-benzodithiolyl, 1,4-benzodioxanyl, chromanyl or chromenyl .

The term acyl as a group or part of the acylamino group refers to an alkanoyl, aroyl, aralkanoyl, alkoxycarbonyl, aryloxycarbonyl or aralkoxycarbonyl group.

The compounds of formula (I) form salt with inorganic and organic acids and the invention includes such salts formed with physiologically acceptable inorganic and organic acids.

A preferred class of compounds of formula (I) are those wherein  $R_1$  is a group (c). When  $R_1$  is the group (c) this is conveniently a group wherein  $X_5$  is oxygen and  $X_6$  is nitrogen or  $X_5$  is  $NR_8$  wherein  $R_8$  is hydrogen or methyl and  $X_6$  is CH.

The group  $R_1$  is preferably a group (c) wherein  $X_5$  is oxygen and  $X_6$  is nitrogen.

Examples of suitable  $R_2$  groups include hydrogen  $C_{1-6}$ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, alkenyl e.g. allyl, alkynyl e.g. propargyl,  $C_{3-7}$  cycloalkyl e.g. cyclopropyl or cyclohexyl,  $C_{3-7}$ cycloalkylalkyl e.g.  $C_{3-7}$ cycloalkylmethyl such as cyclopropylmethyl or cyclobutylmethyl, optionally substituted phenyl such as phenyl or phenyl (substituted by halogen e.g. chlorine, or aminomethyl), heteroaryl such as pyridyl e.g. 3-pyridyl, or triazinyl e.g. 2,4-diamino-1,3,5-triazinyl, alkyl (substituted by amino,  $R_{16}NH$  or  $R_{16}R_{17}N$  such as 2-aminoethyl, 2-dimethylaminoethyl, 2-amino-1-methylethyl, 2-dimethylamino-1-methylethyl), or 4-7 membered heterocyclyl group (such as 4-piperidinyl, t-butyloxycarbonyl-piperidinyl, alkyl [substituted by a 4-7 membered heterocyclyl group e.g. 1-ethylpyrrolidin-2-yl-methyl, 3-(4-methyl piperazinyl-1-yl)propyl]), a 6 membered heteroaryl group fused to a partially saturated carbocyclic ring e.g. 1,2,3,4-tetrahydroisoquinolin-7-yl and the N-t-butoxycarbonyl derivative thereof, alkyl substituted

by optionally substituted phenyl e.g. 1-phenylethyl, alkyl substituted by alkenyloxy e.g. 2-vinyloxyethyl, or alkyl substituted by trifluoromethyl e.g. 2,2,2-trifluoroethyl.

Conveniently the group  $R_3$  is hydrogen or  $R_3$  and  $R_2$  together represent propylene chain.

5           The group  $R_4$  is conveniently hydrogen, halogen e.g. chlorine or fluorine, dimethylamino, phenoxy or hydroxy.

The group  $R_5$  is conveniently hydrogen, alkyl e.g. methyl, halogen e.g. bromine, or chlorine, alkoxy e.g. ethoxy, formyl, acetyl, hydroxymethyl or hydroxy.

$R_6$  is conveniently hydrogen, ethylamino or nitro.

10           Specific preferred compounds according to the invention include:

4-(1-Ethyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine;

4-(1H-Benzoimidazol-2-yl)-furazan-3-ylamine;

4-[2-(Amino-furazan-3-yl)-benzoimidazol-1-yl]-piperidine-1-carboxylic acid tert-butyl ester;

15           4-(1-Piperidin-4-yl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine;

4-[1-(2-Amino-ethyl)-1 H-benzoimidazol-2-yl]-furazan-3-ylamine;

4-[1-(2-Amino-1-methylethyl)-1-H-benzoimidazol-2-yl]furazan-3-ylamine;

4-(5-Bromo-1-ethyl-1 H-benzoimidazol-2-yl)furazan-3-ylamine;

4-(1-Cyclopropyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine;

20           4-(1-Cyclohexyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine;

4-(1-Cyclopropylmethyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine;

4-[1-(2-Dimethylamino-ethyl)-1 H-benzoimidazol-2-yl]-furazan-3-ylamine;

4-[1-(2-Dimethylamino-1-methyl-ethyl)-1 H-benzoimidazol-2-yl]-furazan-3-ylamine;

4-[1-(3-Chlorophenyl)-1-H-benzoimidazol-2-yl]furazan-3-ylamine;

25           4-[1-(4-Chlorophenyl)-1H-benzoimidazol-2-yl]furazan-3-ylamine;

4-(6-Chloro-1-ethyl-1H-benzoimidazol-2-yl)furazan-3-ylamine;

4-(1-Ethyl-5-methoxy-1H-benzoimidazol-2-yl)-furazan-3-ylamine;

- 4-(4-Nitro-1 H-benzimidazol-2-yl)-furazan-3-ylamine;  
 4-(5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2-yl)- furazan-3-ylamine;  
 4-(1-phenyl-1H-benzimidazol-2-yl)- furazan-3-ylamine;  
 4-(5-chloro-6-fluoro-1H-benzimidazol-2-yl)- furazan-3-ylamine;  
 5 4-(1-methyl-1H-benzimidazol-2-yl)- furazan-3-ylamine;  
 4-(6-fluoro-1H-benzimidazol-2-yl)- furazan-3-ylamine;  
 4-(1-pyridin-3-yl-1H-benzimidazol-2-yl)- furazan-3-ylamine;  
 [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzoimidazol-5-yl]-ethanone;  
 2-(4-Amino-furazan-3-yl)-1-ethyl-1 H -benzoimidazole-5-carbaldehyde;  
 10 [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzoimidazol-5-yl]-methanol;  
 2-(4-Aminofurazan-3-yl)-3-ethyl-3H-benzoimidazol-5-ol;  
 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-benzoimidazol-5-ol;  
 4-(1-Ethyl-4-nitro-1 H-benzimidazol-2-yl)-furazan-3-ylamine;  
 4-(1-Ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-3-ylamine;  
 15 4-[1-(2,2,2-Trifluoroethyl)-1H-benzimidazol-2-yl]-furazan-3-ylamine;  
 4-{1-[3-(4-Methylpiperazin-1-yl)propyl]-1H-benzimidazol-2-yl}-furazan-3-ylamine; 4-{1-  
 [(1-Ethylpyrrolidin-2-yl)methyl]-1H-benzimidazol-2-yl}-furazan-3-ylamine;  
 [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzimidazol-4yl]-ethylamine;  
 4-(1-Propyl-1H-benzimidazol-2-yl)-furazan-3-ylamine;  
 20 4-[1-(Cyclobutylmethyl)-1H-benzimidazol-2-yl]-furazan-3-ylamine;  
 4-(1-Butyl-1H-benzimidazol-2-yl)-furazan-3-ylamine;  
 4-(1-Ethyl-5-fluoro-1H-benzimidazol-2-yl)-furazan-3-ylamine;  
 4-(1-Ethyl-6-fluoro-1H-benzimidazol-2-yl)-furazan-3-ylamine;  
 4-{1-[(1S)-1-Phenylethyl]-1H-benzimidazol-2-yl}-furazan-3-ylamine.  
 25 4-[1-Ethyl-6-(methyloxy)-1H-benzimidazol-2-yl]-furazan-3-ylamine  
 2-(4-Amino-1,2,5-furazan-3-yl)-1-ethyl-N,N-dimethyl-1H-benzimidazol-6-amine

- 1,1-Dimethylethyl 7-[2-(4-amino-furazan-3-yl)-6-hydroxy-1H-benzimidazol-1-yl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate
- 2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)-1H-benzimidazol-6-ol
- 1,1-Dimethylethyl 7-[2-(4-amino-furazan-3-yl)-6-fluoro-1H-benzimidazol-1-yl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate
- 4-[1-Ethyl-6-(phenyloxy)-1H-benzimidazol-2-yl]-furazan-3-ylamine

The ability of the compounds of formula (I) to antagonise the effect of the kinase Msk-1 may be determined using published procedures such as those described in WO9967283 and WO0127315. Alternatively the following *in vitro* assay may be used.

Thus the Msk-1 antagonist activity was determined using human recombinant Msk-1 expressed in Sf9 cells (WO9967283). The enzyme underwent prior activation by incubation with MAPK (p42), which was removed prior to storage and subsequent assay.

The assay of Msk-1 activity involved incubation with peptide substrate and ATP<sup>33</sup>, the subsequent incorporation of P<sup>33</sup> into the peptide was quantified by Scintillation Proximity Assay (SPA - Amersham Pharmacia).

For IC<sub>50</sub> determination, test compounds were typically dissolved at 10mM in 100% DMSO, with subsequent serial dilution into 10% DMSO. Compounds were typically assayed over an eleven point dilution range with a concentration in the assay of 10uM to 3nM, in duplicate. IC<sub>50</sub> values were calculated by bespoke curve fitting software.

Assays were performed in clear bottomed, white walled, 384 well plates, in a total assay volume of 12.5ul. The assays contained: 2nM activated MSK1; 2uM biotinylated peptide (biotin-GRPRTSSFAEG-OH); 20uM ATP; 25Bq per pmole ATP<sup>33</sup>; 50mM Hepes; 10mM

MgCl<sub>2</sub>; 0.1mM EDTA; 0.0025% Tween-20; 5mM β-Mercaptoethanol; pH 7.5. The reactions were incubated at 20°C for 60 minutes, then terminated by the addition of 10ul of 200mM EDTA.

- 5 Streptavidin PVT SPA beads were added to a concentration of 0.2mg per well. The plates were shaken for 10 minutes before centrifugation at 2500 rpm for 10 minutes. p<sup>33</sup> incorporation was quantified by scintillation counting in a Wallac Trilux.

The compounds of the invention are therefore useful in the treatment or prevention of diseases and/or conditions mediated through the kinase Msk-1. Thus the  
10 compounds are useful for the treatment or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events or inflammatory conditions.

Examples of such disorders include acute stroke e.g. cerebral stroke, thromboembolic stroke, hemorrhagic stroke and cerebral ischemia, multi infarct dementia , pain, arthritis e.g. rheumatoid arthritis, osteoarthritis, psoriasis, and  
15 enteropathic arthritis, multiple sclerosis, Alzheimers disease, Parkinson's disease , amyotrophic lateral sclerosis, spinal cord injury and asthma. The compounds may also be useful for the treatment of irritable bowel syndrome, inflammatory bowel disease and certain cancers.

The ability of the compounds of formula (I) to antagonise the effect of the kinase  
20 ROCK1 may be determined by using the following assays:

1. ROCK kinase assay:

ROCK inhibitor activity was determined using human recombinant ROCK1 kinase domain (amino acid 1-578) expressed in Sf9 cells (WO9967283). The enzyme was purified using his-tag NTA column and Source15 HPLC chromatography. The assay of  
25 Rock-1 activity involved incubation with peptide substrate and ATP<sup>33</sup>, the subsequent

incorporation of  $P^{33}$  into the peptide was quantified by Scintillation Proximity Assay (SPA - Amersham Pharmacia).

For IC50 determination, test compounds were typically dissolved at 10mM in 100% DMSO, with subsequent serial dilution into 10% DMSO. Compounds were typically assayed over an eleven point dilution range with a concentration in the assay of 10uM to 3nM, in duplicate. IC50 values were calculated by bespoke curve fitting software.

Assays were performed in clear bottomed, white walled, 96 well plates, in a total assay volume of 40ul. The assays contained: 1nM hROCK1; 1uM biotinylated peptide (biotin-Ahx-AKRRRLSSLRA-CONH2); 1uM ATP; 25Bq per pmole ATP $^{33}$ ; 12.5mM Hepes pH7.4; 7.5mM MgCl<sub>2</sub>; 0.015% BSA. The reactions were incubated at 20°C for 120 minutes, then terminated by the addition of 10ul of 200mM EDTA.

Streptavidin PVT SPA beads were added to a concentration of 0.4mg per well. The plates were shaken for 10 minutes before centrifugation at 2500 rpm for 10 minutes.  $P^{33}$  incorporation was quantified by scintillation counting in a Wallac Trilux.

## 2. Aorta artery contraction assay:

Male Sprague-Dawley rats (350-400g) are anesthetized with 5% Isoflurane in O<sub>2</sub> and euthanized by exsanguination. Proximal descending thoracic aortae are removed and placed in oxygenated (95% O<sub>2</sub>, 5% CO<sub>2</sub>) ambient temperature Krebs solution (pH 7.4) with the following composition (mM): NaCl 112.0, KCl 4.7, CaCl<sub>2</sub> 2.5, KH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25.0, dextrose 11.0, indomethacin 0.01, and L-NAME 0.1. The isolated aortae are cut into four 3mm rings and each segment is suspended by two 0.1mm diameter tungsten wire hooks and placed in a 10 mL organ bath containing oxygenated (95% O<sub>2</sub>, 5% CO<sub>2</sub>) 37°C Krebs solution (pH 7.4). The tissues are equilibrated under 1.0 grams resting tension for approximately 30 minutes. Responses



are measured isometrically using a Grass FT 03 force-transducer and recorded on a Grass polygraph (model 7D) as change in tension.

After the equilibration period, each tissue is contracted with 60 mM KCl for about 15 minutes, washed with 37°C Krebs solution, and allowed to relax to the resting tension. The 60mM KCl contraction is repeated. The tissue is then contracted to equilibration with 1  $\mu$ M norepinephrine and washed with 37°C Krebs solution and allowed to relax to the resting tension.

A cumulative concentration-response curve to phenylephrine is obtained by dosing at 0.5 log unit intervals (1nM to 1  $\mu$ M) and the EC<sub>80</sub> is determined. Following several washes, each vessel is contracted to equilibrium with an EC<sub>80</sub> concentration of phenylephrine and tone is reversed by adding cumulative amounts of a ROCK inhibitor at 0.5 log unit intervals (0.1nM to 3  $\mu$ M). When constructing cumulative concentration-response, a higher concentration of vasoactive agent is added to the tissue bath after the previous response has reached a plateau.

15

### 3. In vivo effect of ROCK inhibitors (Intravenous, IV):

Rats are anaesthetised with isoflurane 3% for the implantation of femoral venous and arterial catheters. During the experiment, anaesthesia was maintained at 2%. Each rat received an intravenous bolus dose of vehicle followed by a bolus doses of ROCK inhibitors at 10, 30, 100 and 300 ug/kg with approx 20 minutes between doses. Blood samples are taken at 20 minutes after doses 10, 30 and 300 ug/kg for the subsequent determination of plasma levels of ROCK inhibitors.

Arterial blood pressure and heart rate derived from the blood pressure are recorded on strip chart and also on a computerised data acquisition system (Po-Ne-Mah, V 3.30, Gould Instruments). Hemodynamic data is presented as the maximum change from pre-dose control expressed as means +/- SEM.

25

The compounds of the invention are therefore useful in the treatment or prevention of diseases and/or conditions mediated through Rho kinases-1 and/or -2.

Thus the compounds are useful for the treatment or prophylaxis of cardiovascular diseases such as hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure and atherosclerosis. The compounds are useful for the treatment or prophylaxis of disorders associated with neuroinflammatory diseases such as stroke, spinal cord injury, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and/or inflammatory disorders such as inflammatory pain, as rheumatoid arthritis, irritable bowel syndrome, inflammatory bowel disease.

The compounds are useful for the treatment or prophylaxis of asthma, female sexual dysfunction, male erectile dysfunctions and over-active bladder syndrome, cancer and tumor metastasis, viral and bacterial infections, insulin resistance and diabetes.

The invention therefore provides for the use of a compound of formula (I) and/or physiologically acceptable salts thereof for use in therapy and in particular for use as a medicine for inhibiting the effects of the kinases Msk-1 and/or ROCK(1 and/or 2).

The invention also provides for the use of a compound of formula (I) and/or a physiologically acceptable derivative or salt thereof for the manufacture of a medicament for inhibiting the effects of the kinases Msk-1 and/or ROCK(1 and/or 2).

According to a further aspect, the invention also provides for a method for inhibiting the effects of the kinases Msk-1 and/or ROCK(1 and/or 2) in a mammal e.g. a human, comprising administering to a patient in need thereof an effective amount of a compound of formula (I) and/or a physiologically acceptable derivative or salt thereof.

It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established diseases or symptoms.

It will further be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated, the route of administration and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician. In general however doses employed for adult human treatment will typically be in the range of 5 to 800mg per day, dependent upon the route of administration.

Thus for parenteral administration a daily dose regimen will typically be in the range 0.1 to 80mg/kg of the total body weight, preferably from about 0.2 to 30mg /kg or more preferably 0.5 to 15mg/kg.. For oral administration a daily dose regimen will typically be within the range range 0.1 to 80mg/kg of the total body weight, preferably from about 0.2 to 30mg /kg or more preferably 0.5 to 15mg/kg.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

Preferred routes of administration include by intravenous injection or orally.

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.

The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The compositions of the invention include those in a form especially formulated for oral, buccal, parenteral, inhalation or insufflation, implant or rectal administration.

Appropriate dosage forms for administration by each of these routes may be prepared by conventional techniques.

Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, 5 mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch or sodium starch glycollate, or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well 10 known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, 15 hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; solubilizers such as surfactants for example polysorbates or other agents such as cyclodextrins; and 20 preservatives, for example, methyl or propyl p-hydroxybenzoates or ascorbic acid. The compositions may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

25 The composition according to the invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may be presented in unit dose form in ampoules, or in multi-dose containers with an added


preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Coveniently the compounds of the invention are formulated for intravenous or oral administration.




The compositions according to the invention may contain between 0.1-99% of the active ingredient, conveniently from 30-95% for tablets and capsules and 3-50% for liquid preparations.

The invention further provides novel compounds within the scope of the general formula (I), examples of such novel compounds include the compounds, the synthesis of which are specifically described in the examples.

Compounds of formula (I) wherein  $R_1$  is a group (a), (c) and (d) may be prepared by reacting the diamine (II)



wherein  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  have the meanings defined in (I) with the appropriate compound of formula (III), (IV) or (V)



(III)


(IV)

(V)

- wherein Z is hydrogen, halogen e.g. Cl, Br or I, hydroxy or C<sub>1-4</sub>alkoxy, Ra is hydrogen or a nitrogen protecting group such as an alkoxycarbonyloxy or benzyloxycarbonyloxy group and each of X<sub>1</sub>, X<sub>2</sub>, X<sub>5</sub>, X<sub>6</sub>, X<sub>7</sub>, X<sub>8</sub> and X<sub>9</sub> have the meanings as defined in formula (I) or is a group available thereto, followed when required by removal of the nitrogen protecting group Ra using conventional methods.

- When Z is a group selected from halogen, alkoxy or hydroxy the reaction is carried out with heating and optionally in the presence of a solvent and/or a dehydrating agent such as polyphosphoric acid.
- When Z is hydrogen the reaction is conveniently carried out in the presence of an oxidant such as sodium bisulphite.


Compounds of formula (I) wherein R<sub>1</sub> is the group (b) may be prepared by reduction of the corresponding nitro derivative (VI)



(VI)

- wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, X<sub>3</sub> and X<sub>4</sub> have the meanings defined in formula (I). The reduction may be effected using conventional procedures for converting a nitro group into an amino group, thus for example the reduction may be effected using hydrogen and a suitable metal catalyst e.g. palladium.

- Compounds of formula (I) wherein R<sub>1</sub> is the group (c) and X<sub>5</sub> is oxygen and X<sub>6</sub> is nitrogen may be prepared by reacting the nitrile (VII)




(VII)

wherein  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  have the meanings defined in formula (I) with hydrochloric acid and sodium nitrite in a solvent such as an alkanol and treatment of the product thus formed with a base e.g. aqueous sodium hydroxide and hydroxylamine and subsequent  
 5 heating.

Alternatively compounds of formula (I) wherein  $R_1$  is the group (c) and  $X_5$  is oxygen and  $X_6$  is nitrogen may be prepared by reacting the diamine (II) with 5-methyl-[1,4,5] oxadiazolo [3,4-d] pyrimidin-7-ol in glacial acetic acid and with heating. In a modification of this process the reaction may be carried out using a derivative of the  
 10 diamine(II) wherein the primary amino group is in a protected form e.g. as a t-butoxycarbonylamino group.

Compounds of formula (I) wherein  $R_1$  represent the group (c) wherein  $X_5$  is NH and  $X_6$  is CH may be prepared by reacting compound (VIII)



(VIII)

15

wherein  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_1$  have the meanings defined in formula (I) with hydrazine. This reaction is preferably carried out in a solvent e.g. an alkanol such as methanol and with heating.

In another aspect of the invention compounds of formula (I) may be converted into other compounds of formula (I).

Thus compounds wherein  $R_2$  is an optionally substituted alkyl group may be prepared by treating the corresponding compound wherein  $R_2$  is hydrogen with the  
5 appropriate optionally substituted alkyl halide in a solvent such as DMF and in the presence of a base such as sodium hydride or cesium carbonate.

Compounds of formula (I) wherein  $R_5$  is an acetyl group may be prepared by treating the corresponding compound of formula (I) wherein  $R_5$  is halogen e.g. bromine with (1-ethoxyvinyl)tributyl tin and bis(triphenylphosphine) palladium (II) chloride in a solvent  
10 such as toluene. Conveniently the reaction is carried out with heating in an atmosphere of argon.

Compounds of formula (I) wherein  $R_5$  is a formyl group may be prepared by treating the corresponding compound of formula (I) wherein  $R_5$  is halogen e.g. bromine with bis(triphenylphosphine) palladium (II) chloride and sodium formate in a solvent such  
15 as DMF. Conveniently the reaction is carried out with heating in an atmosphere of carbon monoxide.


A compound of formula (I) wherein  $R_5$  is hydroxymethyl may be prepared by reaction of the corresponding compound of formula (I) wherein  $R_5$  is formyl using sodium borohydride in a solvent such as an alkanol e.g. anhydrous methanol.

20 The nitrile of formula (VII) may be prepared by heating of a compound of formula (II) with ethyl cyanoacetate.

The compound of formula (VIII) may be prepared by reacting the nitrile of formula (VII) with an acetal of N, N dimethylformamide in a solvent e.g. a hydrocarbon such as ortho xylene and with heating.


25 Compounds of formula (VI) may be prepared by reaction of the 2-iodo-benzimidazole derivative (IX)






(IX)

wherein  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  have the meanings defined in formula (I) with the compound (X)



(X)


- 5 wherein  $X_3$  and  $X_4$  have the meanings defined in formula (I) in the presence of a base and a polar aprotic solvent and then reacting the resultant compound (XI)



(XI)


with an alkyl nitrite in the presence of a suitable base.

- 10 Compounds of formula (II) may be prepared by reacting a compound of formula (XII)



(XII)

wherein  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  have the meanings defined above and L is a group displaceable by the amine  $R_2NH_2$  e.g. methoxy, bromine, chlorine, fluorine or methoxysulphonyl to give the nitro amine (XIII)



(XIII)

- 5 followed by reduction of the nitro group by conventional means, for example using hydrogen and a palladium catalyst, iron and an organic acid e.g. acetic acid or with sodium dithionite.


When compounds of formula (I) contain an asymmetric centre the specific enantiomers arising there from may be obtained by conventional procedures. For  
 10 example using preparative high performance liquid chromatography (HPLC) with a chiral stationary phase.

Physiologically acceptable acid addition salts of the compounds of formula (I) wherein one of the groups  $R_1$  to  $R_5$  contain a basic nitrogen atom may be prepared by conventional procedures. Thus by addition of a solution of the inorganic or organic acid  
 15 in a suitable solvent e.g. an alkanol or an ether to a solution of the free base in a solvent such as an alkanol e.g. methanol or an ether e.g. diethyl ether or tetrahydrofuran.

The compounds of formula (III), (IV), (V) (IX), (X) and (XII) are either known compounds or may be prepared by analogous methods to those preparing the known compounds.

The following examples are illustrative of the present invention and are not to be  
 20 construed as a limitation of the scope of the invention.


**Intermediate 1.** 5-Methyl-[1,2,5]oxadiazolo[3,4-d]pyrimidin-7-ol



A solution of 4-amino-6-hydroxy-2-methyl-5-nitrosopyrimidine (20g, 130mmol) in acetic acid (800ml) was treated portionwise with lead tetraacetate (86g, 195mmol) and stirred overnight at room temperature. The solvent was evaporated in vacuo and the residue partitioned between ethyl acetate and water. The organic phase was washed with water and saturated sodium bicarbonate solution, dried over magnesium sulphate and concentrated in vacuo. Trituration of the residue with dichloromethane afforded the title compound (6.33g, 32%). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>); 12.65 (1H, br s), 2.38 (3H, s).


10

**Example 1: 4-(1-Ethyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine**




A mixture of N-ethylbenzene-1,2-diamine (212mg, 1.56mmol) (Weidenhagan et. al., Chem. Ber.; 1942, 75, 1936) and 4-aminofurazan-3-carboxylic acid (200mg, 1.5mmol) was added to polyphosphoric acid (2ml) and the mixture was stirred at 180°C for 1hour. After cooling to room temperature the reaction mixture was added to saturated potassium carbonate solution and extracted with ethyl acetate. The organic phase was concentrated in vacuo and the residue purified by silica gel chromatography eluting with 10% ethyl acetate in hexanes, to afford the title compound, (20mg, 6%); MS (AP+) m/e 230 [M+H]<sup>+</sup>.

20

**Example 2: 4-(1H-Benzoimidazol-2-yl)-furazan-3-ylamine**

- 5 To a solution of (1 H-benzoimidazol-2-yl)acetonitrile (5.0g, 31.8mmol) in hydrochloric acid (2N, 100ml) and methanol (50ml) was added sodium nitrite (4.3g, 63.6mmol) portionwise. After stirring at room temperature for 3 hours, the mixture was basified to pH10 with 50% sodium hydroxide solution, hydroxylamine (20ml) was added and the solution refluxed for 18 hours. The mixture was cooled and the precipitate collected to
- 10 afford the title compound (1.8g, 22%); MS (AP+) m/e 202 [M+H]<sup>+</sup>.


**Example 3: 4-[2-(Amino-furazan-3-yl)-benzoimidazol-1-yl]-piperidine-1-carboxylic acid tert-butyl ester**

- 15 A stirred solution of the product of Example 2 (600mg, 3mmol), 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (600mg, 3mmol) and triphenyl-phosphine (1.18g, 4.5mmol) in tetrahydrofuran (7ml) at 0°C was treated with diethyl azodicarboxylate (0.71ml, 4.5mmol). The solution was stirred at room temperature for 4 hours and the solvent was removed in vacuo. The residue was purified by silica gel

chromatography eluting with 0.880 ammonia:ethanol:hexane (1:9:40) to afford the title compound (160mg, 13%); MS (ES+) m/e 385 [M+H]<sup>+</sup>.

**Example 4: 4-(1-Piperidin-4-yl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine**

5




The product of Example 3 (160mg, 0.41mmol) was stirred in trifluoroacetic acid (2ml) and dichloromethane (4ml) at room temperature for 3 hours and the solution was then co-evaporated with dichloromethane. The residue was purified by silica gel chromatography eluting with 0.880 ammonia:ethanol:hexane (1:9:200), to afford the title compound (50mg, 42%); MS (ES+) m/e 285 [M+H]<sup>+</sup>.

10

**Example 5: 4-[1-(2-Amino-ethyl)-1 H-benzoimidazol-2-yl]-furazan-3-ylamine**


15



To a solution of the product of Example 2 (250mg, 1.24mmol) in N,N-dimethylformamide (2ml) at 0°C was added sodium hydride (60% suspension in mineral

oil, 55mg, 1.37mmol). The mixture was stirred at 0°C for 15 minutes then treated with additional sodium hydride (55mg, 1.37mmol) followed by 2-chloroethylamine hydrochloride (160mg, 1.37mmol) and the mixture was stirred at 70°C overnight. On cooling, the mixture was poured into saturated aqueous sodium hydrogen carbonate solution. The mixture was extracted with ethyl acetate (2x) and the organic phase washed with saturated aqueous sodium chloride solution, dried over magnesium sulphate and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with 5% methanol in dichloromethane, triturated with ether, filtered and dried in vacuo to afford the title compound (80mg, 26%); MS (AP+) m/e 245 [M+H]<sup>+</sup>.

**Example 6: 4-[1-(2-Amino-1-methylethyl)-1-H-benzoimidazol-2-yl]furan-3-ylamine**



**Step 1. 2-[2-(4-Amino-furazan-3-yl)-benzoimidazol-1-yl]-propanitrile**

The title compound was prepared from the product of Example 2 and 2-chloropropanitrile using the method of Example 5; MS (AP+) m/e 255 [M+H]<sup>+</sup>.


**Step 2. 4-[1-(2-Amino-1-methylethyl)-1H-benzoimidazol-2-yl]furan-3-ylamine**

The product from Step 1 (150mg, 0.59mmol) in dry tetrahydrofuran (5ml) was treated under argon with a 1.0M borane-tetrahydrofuran complex (1.24ml, 1.24mmol) and heated under reflux for 3 hours. After cooling to room temperature, methanol was added dropwise, followed by 2M hydrochloric acid, and the mixture was heated under reflux for

90 minutes. After cooling to room temperature, the solvent was removed in vacuo and the residue partitioned between 10% aqueous sodium hydroxide solution and dichloromethane. The organic phase was separated, dried over magnesium sulphate and concentrated in vacuo to afford the title compound (40mg, 27%); MS (ES+) m/e 259

5 [M+H]<sup>+</sup>.

**Example 7: 4-(5-Bromo-1-ethyl-1 H-benzoimidazol-2-yl)furazan-3-ylamine**



10

**Step 1. (4-Bromo-2-nitrophenyl)ethylamine**

5-Bromo-2-fluoronitrobenzene (1.2g, 5.7mmol) in ethanol (4 ml) was cooled to 0°C and treated with a 70% solution of ethylamine in water (4ml). After warming to room temperature, the mixture was stirred for 30 minutes and the title compound (1.25g, 85%)

15 was collected and dried in vacuo; <sup>1</sup>H NMR (CDCl<sub>3</sub>) 8.31 (1H, d, J 1Hz), 7.95 (1H, br s), 7.49 (1H, dd, J 8.5, 1Hz), 6.75 (1H, d, J 8.5Hz), 3.34 (2H, m), 1.37 (3H, t, 8.5Hz).

**Step 2. 4-Bromo-N<sup>1</sup>-ethylbenzene-1,2-diamine**

The product from Step 1 (1.25g, 4.8mmol) was treated with a solution of tin (II) chloride (3.20g, 16.9mmol) in concentrated hydrochloric acid (4.25ml) and stirred at 50°C for 1 hour. After cooling to room temperature, the reaction mixture was poured into 10% sodium hydroxide solution, extracted into ethyl acetate, and the organic phase washed with saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated in vacuo to afford the title compound (800mg, 76%); <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)

6.66 (1H, d, J 1Hz), 6.57 (1H, dd, J 8.5, 1 Hz), 6.29 (1H, d, J 8.5 Hz), 4.81 (2H, br s), 4.45 (1H, br m), 3.00 (2H, m), 1.19 (3H, t, J8.5 Hz)

**Step 3. 4-(5-Bromo-1-ethyl-1 H-benzoimidazol-2-yl)furazan-3-ylamine**

- 5 The product from Step 2 (500mg, 2.9mmol) and Intermediate 1 (290mg, 1.9mmol) in glacial acetic acid (5ml) were heated under reflux for 3 hours. After cooling to room temperature, the acetic acid was removed in vacuo and the residue triturated with dichloromethane, filtered and dried in vacuo to afford the title compound (100mg, 17%); MS (AP+) m/e 308/310 [M+H]<sup>+</sup>.

- 10 The following examples were prepared from 2-fluoronitrobenzene and the appropriate amine by the general method described in Example 7, Steps 1-3.

	Example	Amine	Characterisation
8	4-(1-Cyclopropyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine	Cyclopropylamine	MS (AP+) m/e 242 [M+H] <sup>+</sup>
9	4-(1-Cyclohexyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine	Cyclohexylamine	MS (AP+) m/e 284 [M+H] <sup>+</sup>
10	4-(1-Cyclopropylmethyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine	C-Cyclopropyl-methylamine	MS (AP+) m/e 256 [M+H] <sup>+</sup>
11	4-[1-(2-Dimethylamino-ethyl)-1 H-benzoimidazol-2-yl]-furazan-3-ylamine	N <sup>1</sup> , N <sup>1</sup> -Dimethyl-ethane-1,2-diamine	MS (AP+) m/e 273 [M+H] <sup>+</sup>



12	4-[1-(2-Dimethylamino-1-methyl-ethyl)-1-H-benzoimidazol-2-yl]-furazan-3-ylamine	N <sup>1</sup> , N <sup>1</sup> -Dimethyl-propane-1,2-diamine	MS (AP+) m/e 287 [M+H] <sup>+</sup>
13	4-[1-(3-Chlorophenyl)-1-H-benzoimidazol-2-yl]furazan-3-ylamine	3-Chloroaniline	MS (AP+) m/e 312/314 [M+H] <sup>+</sup>
14	4-[1-(4-Chlorophenyl)-1-H-benzoimidazol-2-yl]furazan-3-ylamine	4-Chloroaniline	MS (AP+) m/e 312/314 [M+H] <sup>+</sup>


The following examples were prepared from Intermediate 1 and the appropriate 1,2-diamine by the general method described in Example 7, Step 3.

	Example	1,2-Diamine	Characterisation
15	4-(6-Chloro-1-ethyl-1H-benzoimidazol-2-yl)furazan-3-ylamine	4-Chloro-N <sup>2</sup> -ethyl-benzene-1,2-diamine (Davoll et. al.; J. Chem. Soc. 1960, 314)	MS (AP-) m/e 262/264 [M-H] <sup>-</sup>
16	4-(1-Ethyl-5-methoxy-1H-benzoimidazol-2-yl)-furazan-3-ylamine	N <sup>1</sup> -ethyl-4-methoxy-benzene-1,2-diamine (Tanaka et. al. Chem. Pharm. Bull. 1981, 29, 1876).	MS (ES+) m/e 260 [M+H] <sup>+</sup>
17	4-(4-Nitro-1 H-benzimidazol-2-	3-Nitro-benzene-1,2-	MS (ES+) m/e


	yl)-furazan-3-ylamine	diamine	245 [M+H] <sup>+</sup> .
18	4-(5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2-yl)-furazan-3-ylamine	1,2,3,4-tetrahydroquinoline-8-amine	MS (ES+) 242 [M+H];
19	4-(1-phenyl-1H-benzimidazol-2-yl)- furazan-3-ylamine	N-phenylbenzene-1,2-diamine	MS (ES+) 278 [M+H];
20	4-(5-chloro-6-fluoro-1H-benzimidazol-2-yl)- furazan-3-ylamine	3-chloro-4-fluoro-1,2-phenylenediamine	MS (ES+) 254 [M+H];
21	4-(1-methyl-1H-benzimidazol-2-yl)- furazan-3-ylamine	N-methylbenzene-1,2-diamine	MS (ES+) 215 [M+H];
22	4-(6-fluoro-1H-benzimidazol-2-yl)- furazan-3-ylamine	4-fluorobenzene-1,2-diamine	MS (ES+) 220 [M+H];

23	4-(1-pyridin-3-yl-1H-benzimidazol-2-yl)-furazan-3-ylamine	N-pyridin-3-ylbenzene-1,2-diamine	MS (ES+) 279 [M+H];
----	---	-----------------------------------	------------------------


**Example 24: [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzimidazol-5-yl]-ethanone**



To a solution of the product of Example 7 (200mg, 0.649mmol) in anhydrous  
 5 toluene (15ml), was added (1-ethoxyvinyl)tributyl tin (0.241ml, 0.714mmol) followed by  
 bis(triphenylphosphine)palladium (II) dichloride (45mg, 0.0649mmol), and the reaction  
 heated under reflux for 16 hours under an argon atmosphere. The solvent was  
 evaporated in vacuo and the residue dissolved in methanol (5ml) and 2N hydrochloric  
 acid (1.95ml) and stirred for 15 minutes at room temperature. The solvent was  
 10 evaporated in vacuo, neutralised with saturated sodium bicarbonate solution, diluted with  
 dichloromethane, and the resulting precipitate collected by filtration. The crude product  
 was triturated with hot methanol, and dried in vacuo to afford the title product (45mg,  
 26%). MS (ES+) m/e 272 [M+H]<sup>+</sup>.


**Example 25: 2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzoimidazole-5-carbaldehyde**

To a solution of the product of Example 7 (180mg, 0.584mmol) in anhydrous  
5 N,N-dimethylformamide (10ml) was added bis(triphenylphosphine)palladium (II)  
dichloride (40mg, 0.0584mmol), followed by sodium formate (120mg, 1.752mmol), and  
the reaction was maintained under atmospheric pressure of carbon monoxide and  
heated at 100°C for 16 hours. The solvent was evaporated in vacuo, and the residue  
partitioned between ethyl acetate and saturated sodium bicarbonate solution. The  
10 organic phase was then washed with water (x3), dried over anhydrous sodium sulphate,  
and evaporated in vacuo to yield a residue. The crude residue was purified by silica gel  
chromatography eluting with a mixture of ethyl acetate/hexane (1:2.5) to afford the title  
product (22mg, 15%). MS (ES+) m/e 258 [M+H]<sup>+</sup>.

**15 Example 26: [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzoimidazol-5-yl]-methanol**

To a solution of the product of Example 25 (21mg, 0.082mmol) in anhydrous methanol was added sodium borohydride (3.4mg, 0.090mmol). After stirring for 2 hours at room temperature, the solvent was evaporated in vacuo and the residue dissolved in dichloromethane, and the organic phase washed with saturated sodium bicarbonate solution, then water and dried over anhydrous sodium sulphate. The solvent was then  
5 evaporated in vacuo to afford the title product (19mg, 90%). MS (ES+) m/e 260 [M+H]<sup>+</sup>.

**Example 27: 2-(4-Aminofurazan-3-yl)-3-ethyl-3H-benzimidazol-5-ol**



10

**Step 1. [2-(3-Fluoro-4-nitrophenoxy)ethoxy]trimethylsilane**

3-Fluoro-4-nitrophenol (2.8g, 18.3mmole) in dry N,N-dimethylformamide (10ml) was cooled to 0°C and treated with a 60% suspension of sodium hydride in mineral oil  
15 (810mg, 20.2mmol). The mixture was stirred at room temperature for 15 minutes. 2-(Trimethylsilyl)ethoxymethyl chloride (3.6ml, 20.2mmol) was added dropwise and the mixture stirred for 18 hours at room temperature. The reaction mixture was poured into water, extracted (x3) into dichloromethane and the organic phase washed with saturated aqueous sodium chloride solution, dried over magnesium sulphate and concentrated in  
20 vacuo to afford the title compound (5.0g, 95%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) 8.07 (1H, t, J 8.5Hz), 6.96 (2H, m), 5.28 (2H, s), 3.75 (2H, t, J 8.5Hz), 0.93 (2H, t, J 8.5Hz).

**Step 2. Ethyl-[2-nitro-5-(2-trimethylsilyl-ethoxymethoxy)-phenyl]-amine**

The product from Step 1 (5.0g, 17.4mmole) in ethanol (12ml) was treated with a 70% solution of ethylamine in water (12ml) and heated at 60°C for 18 hours. After cooling to room temperature, the solvent was removed in vacuo and the residue dissolved in  
5 dichloromethane, washed with water and saturated aqueous sodium chloride solution, dried over magnesium sulphate and concentrated in vacuo to afford the title compound (4.6g, 85%); MS (ES+) m/e 313 [M+H]<sup>+</sup>.

**Step 3. N<sup>2</sup>-Ethyl-4-(2-trimethylsilylethoxymethoxy)benzene-1,2-diamine**

10 The product from Step 2 (4.6g, 14.7mmole) in ethanol (150ml) was hydrogenated for 18 hours in the presence of 10% palladium on carbon. After filtration of the catalyst through Kieselguhr, the filtrate was concentrated in vacuo to afford the title compound (4.1g, 100%); MS (AP+) m/e 283 [M+H]<sup>+</sup>.


**Step 4. 1-Ethyl-6-(2-trimethylsilylethoxymethoxy)-1H-benzoimidazole-2-carbonitrile**

The product of Step 3 (1.47g, 5.2mmol) and ethyl cyanoacetate (0.83ml, 7.9mmol) was heated to 190°C for 20 minutes. After cooling to room temperature the mixture was purified by silica gel chromatography eluting with 25-60% ethyl acetate in hexanes, to  
20 afford the title compound, (300mg, 17%), MS (ES+) m/e 332 [M+H]<sup>+</sup>.

**Step 5. 2-(4-Aminofurazan-3-yl)-3-ethyl-3-H-benzoimidazol-5-ol**


The title compound was prepared from the product of Step 4 using the method described in Example 2; MS (ES+) m/e 246 [M+H]<sup>+</sup>.

25


**Example 28: 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-benzoimidazol-5-ol**

The title compound was prepared from 4-chloro-3-nitrophenol using the general methods described in Example 27 Steps 1-5; MS (ES+) m/e 246 [M+H]<sup>+</sup>.

5

**Example 29: 4-(1-Ethyl-4-nitro-1 H-benzimidazol-2-yl)-furazan-3-ylamine**

- 10 The title compound was prepared from the product of Example 17 and ethyl iodide using the method of Example 5; MS (ES+) m/e 275 [M+H]<sup>+</sup>.

**Example 30: 4-(1-Ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-3-ylamine****15 Step 1. (1-Ethyl-1H-benzoimidazol-2-yl)-acetonitrile**

A solution of (1H-benzoimidazol-2-yl)-acetonitrile (1.57g, 0.75mmol) in N,N-dimethylformamide (20ml) containing cesium carbonate (3.3g, 10mmol) was treated with

ethyl iodide (1.56g, 0.8ml, 10mmol). After stirring at room temperature for 5 hours the mixture was filtered through filter aid and the filter pad washed with ethyl acetate. The filtrates were combined, washed with water and brine, dried and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with ethyl acetate, to afford the title compound, (610mg, 33%); MS (AP+) m/e 186 [M+H]<sup>+</sup>.


### Step 2. Dimethylamino-(1-ethyl-1H-benzoimidazol-2-yl)-acrylonitrile

The product of Step 1 (1.86g, 10mmol) and N,N-dimethylformamide dimethylacetal (1.19g, 1.3ml, 10mmol) in ortho-xylene (10ml) was heated under reflux for 1 hour. After cooling, the solution was concentrated and the residue co-evaporated with toluene (x3) to afford the title compound (2.06g, 86%); MS (ES+) m/e 241 [M+H]<sup>+</sup>.

### Step 3. 4-(1-Ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-3-ylamine

The product of Step 2 (381mg, 1.8mmol) and hydrazine hydrate (180mg, 3.6mmol) in methanol (10ml) was heated under reflux for 5 hours. After cooling, the reaction mixture was concentrated in vacuo and the residue purified by silica gel chromatography eluting with 10% methanol in chloroform, to afford the title compound (203mg, 57%); MS (ES+) m/e 200 [M+H]<sup>+</sup>.


### Example 31: 4-[1-(2,2,2-Trifluoroethyl)-1H-benzimidazol-2-yl]-furazan-3-ylamine





A solution of 1,1,1-difluoro-2-iodoethane (1mL) and the product of Example 2 (0.056g, 0.28mmol) in N,N-dimethylformamide (3mL) was treated with cesium carbonate (560mg) and the mixture heated to 100°C for 2 hours. After cooling the reaction mixture was concentrated to dryness and diluted with ethyl acetate and water. The organic layer  
5 was separated, dried over magnesium sulfate and concentrated in vacuo and the residue was purified by silica gel chromatography to yield the title compound (26mg, 33%); MS (ES+) m/e 284 [M+H]<sup>+</sup>.

**Example 32: 4-{1-[3-(4-Methylpiperazin-1-yl)propyl]-1H-benzimidazol-2-yl}-furazan-3-ylamine**



10

**Step 1. [3-(4-Methylpiperazin-1-yl)propyl]-(2-nitrophenyl)amine**

2-Fluoronitrobenzene (1.0g, 7.1mmol) in tetrahydrofuran (25 ml) was treated with 1-(3-aminopropyl)-4-methylpiperazine (1.6g, 10mmol) and potassium carbonate (1.0g, 7.8mmol). The resulting mixture was stirred at room temperature for 16h, and the  
15 mixture diluted with water and ethyl acetate. The organic extracts were collected and dried over magnesium sulfate, the filtrate was concentrated in vacuo and the residue was purified by silica gel chromatography to yield the title compound (1.5g, 76%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.28 (1H, br t), 8.20 (1H, d), 7.45 (1H, dd), 6.92 (1H, d), 6.65 (1H, dd), 3.42 (2H, q), 2.36-2.64 (10H, br m), 2.34 (3H, s), 1.92 (2H, m).

20


**Step 2. N-[3-(4-Methylpiperazin-1-yl)propyl]benzene-1,2-diamine**

The product from Step 1 (1.5g, 5.4mmol) in methanol (40ml) containing 10% palladium on carbon (200mg) was hydrogenated at 45 psi. The mixture was filtered through silica gel and the filtrate was concentrated in vacuo. The resulting dark oil was stirred vigorously in diethyl ether, allowed to settle and the supernatant liquid was decanted and concentrated to an oil to afford the title compound (0.70g, 52%); <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 6.40-6.60 (4H, br m), 4.45 (2H, br s), 3.38 (1H, br s), 3.02 (2H, t), 2.25-2.50 (10H, br m), 2.18 (3H, s), 1.75 (2H, m).


**Step 3. 4-{1-[3-(4-Methylpiperazin-1-yl)propyl]-1H-benzimidazol-2-yl}-furazan-3-ylamine**

The product from Step 2 (270mg, 1.1mmol) and Intermediate 1 (80mg, 0.5mmol) in glacial acetic acid (5ml) were heated under reflux for 3 hours. After cooling to room temperature, the acetic acid was removed in vacuo and the residue triturated with dichloromethane, filtered and dried in vacuo to afford the title compound (84mg, 49%); MS (ES+) m/e 342 [M+H]<sup>+</sup>.

**Example 33: 4-{1-[(1-Ethylpyrrolidin-2-yl)methyl]-1H-benzimidazol-2-yl}-furazan-3-ylamine**



The title compound was prepared from 2-fluoronitrobenzene and 2-(aminomethyl)-1-ethylpyrrolidine by the general method described in Example 32, Steps 1-3. MS (ES+) m/e 313 [M+H]<sup>+</sup>.

**Example 34: [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzimidazol-4-yl]-ethylamine****Step 1. N,N'-Diethyl-2-nitrobenzene-1,3-diamine**

- 5    2,6-Difluoronitrobenzene (1.0g, 6.3mmol) was treated with 70% ethylamine in water (10mL) and stirred at room temperature for 3h. The mixture was diluted with water and the precipitate was collected washed with water and dried to afford the title compound (1.3g, 98%); <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 8.42 (2H, br t), 7.22 (1H, t), 6.00 (2H, d), 3.25 (4H, m), 1.12 (6H, t).

10

**Step 2. N<sup>1</sup>,N<sup>3</sup>-Diethylbenzene-1,2,3-triamine**


- The product from Step 1 (0.3g, 1.4mmol) in methanol (15ml) containing 10% palladium on carbon (6mg) was hydrogenated at 45 psi. The mixture was filtered through silica gel and the filtrate was concentrated in vacuo. The residue was triturated with hexanes and
- 15    the solid was collected to afford the title compound (0.16g, 64%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) 6.85 (1H, t), 6.38 (2H, d), 2.60-3.40 (8H, br m), 1.16 (6H, t).

**Step 3. [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-benzimidazol-4-yl]-ethylamine**

- The product from Step 2 (92mg, 0.51mmol) and Intermediate 1 (62mg, 0.4mmol) in
- 20    glacial acetic acid (2ml) were heated under reflux for 0.5 hours. After cooling to room temperature, the acetic acid was removed in vacuo and the residue dissolved in ethyl acetate and washed with solution of dilute sodium bicarbonate. The organics were dried over magnesium sulfate and the filtrate was concentrated in vacuo. The residue was

purified by silica gel chromatography to afford the title compound (12mg, 10%); MS (ES+) m/e 273 [M+H]<sup>+</sup>.

**Example 35: 4-(1-Propyl-1H-benzimidazol-2-yl)-furazan-3-ylamine**



5


A solution of 1-iodopropane (0.05mL, 0.5mmol) and the product of Example 2 (0.051g, 0.25mmol) in N,N-dimethylformamide (2mL) was treated with cesium carbonate (82mg) and the mixture stirred at room temperature for 3h. The reaction was concentrated in vacuo and the residue partitioned between ethyl acetate and water. The organic extract was separated, dried over magnesium sulfate and the filtrate was concentrated in vacuo. The residue was triturated with diethyl ether to give the title compound (33mg, 54%); MS (ES+) m/e 244 [M+H]<sup>+</sup>.

10

The following examples were prepared from the product of Example 2 and the appropriate halide by the general method described in Example 35.

15

	Example	Halide	Characterisation
36	4-[1-(Cyclobutylmethyl)-1H-benzimidazol-2-yl]-furazan-3-ylamine	Bromomethyl-cyclobutane	MS (ES+) m/e 270 [M+H] <sup>+</sup>
37	4-(1-Butyl-1H-benzimidazol-2-yl)-furazan-3-ylamine	1-Bromobutane	MS (ES+) m/e 270 [M+H] <sup>+</sup>

**Example 38: 4-(1-Ethyl-5-fluoro-1H-benzimidazol-2-yl)-furazan-3-ylamine****Step 1. (2-Amino-5-fluorophenyl)-carbamic acid tert-butyl ester**


- 5 A mixture of 4-fluorobenzene-1,2-diamine (6.9g, 55mmol) and di(tert-butyl) dicarbonate (12g, 55mmol) was warmed to 50°C and stirred until homogeneous (10 min). The mixture was partitioned between ethyl acetate and water. The organic extracts were combined, washed with water and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was triturated with hexanes to afford the title compound (9.1g, 73%); <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 8.25 (1H, br s), 7.11 (1H, m), 6.48 (1H, m), 6.31 (1H, m), 5.15 (2H, br s), 1.51 (9H, s).
- 10

**Step 2. (2-Ethylamino-5-fluorophenyl)-carbamic acid tert-butyl ester**


- A solution of the product from Step 1 (9.1g, 40mmol) in tetrahydrofuran (100mL) was treated with solid potassium tert-butoxide (5.37g, 48mmol). Iodoethane (3.8ml, 48mmol) was added dropwise and the mixture was stirred at room temperature for 1h. The reaction mixture was diluted with ethyl acetate and water and the organic layer was separated, washed with water and brine and dried over magnesium sulfate. The solvent was concentration in vacuo and the residue recrystallised from diethyl ether to afford the title compound (3.9g, 38%); <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 6.85 (1H, m), 6.48 (1H, m), 6.29 (1H, m), 5.21 (1H, br s), 3.67 (2H, m), 3.14 (1H, m), 1.38 (9H, s), 1.02 (3H, t).
- 15
- 20

**Step 3. 4-(1-Ethyl-5-fluoro-1H-benzimidazol-2-yl)-furazan-3-ylamine**

The product from Step 2 (2.13g, 8.6mmol) and Intermediate 1 (1.05g, 6.9mmol) in glacial acetic acid (10ml) were heated to reflux for 3 hours. After cooling to room temperature, the acetic acid was removed in vacuo and the residue triturated with dichloromethane, filtered and dried in vacuo to afford the title compound (0.91g, 43%); MS (ES+) m/e 248 [M+H]<sup>+</sup>; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 7.90 (1H, m), 7.66 (1H, m), 7.36 (1H, m), 6.99 (2H, br s), 4.72 (2H, q), 1.20 (3H, t).

**Example 39: 4-(1-Ethyl-6-fluoro-1H-benzimidazol-2-yl)-furazan-3-ylamine**

The title compound was prepared from 2,4-difluoronitrobenzene and aqueous ethyl amine using the procedures described in Example 32, Step 1-3; MS (ES+) m/e 248 [M+H]<sup>+</sup>; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 7.88 (1H, dd), 7.76 (1H, m), 7.28 (1H, m), 6.98 (2H, br s), 4.71 (2H, q), 1.38 (3H, t), 1.38 (3H, t).

**Example 40: 4-{1-[(1S)-1-Phenylethyl]-1H-benzimidazol-2-yl}-furazan-3-ylamine**

The title compound was prepared from 2-fluoronitrobenzene and (S)-1-phenylethylamine using the procedures described in Example 32, Step 1-3; <sup>1</sup>H NMR


(DMSO-d<sub>6</sub>) 7.84 (1H, d), 7.36 (6H, m), 7.17 (2H, m), 7.09 (1H, m), 6.06 (2H, br s), 1.38 (3H, d).

The following examples were obtained from commercial sources as indicated:

	Example	Source
41	6-[2-(4-Amino-furazan-3-yl)-benzoimidazole-1-ylmethyl]-[1,3,5]triazine-2,4-diamine	ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127 USA
42	[2-(4-Amino-furazan-3-yl)-benzoimidazole-1-yl]-acetonitrile	ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127 USA
43	4-(1-Allyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine	ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127 USA
44	4-(1-Isopropyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine	ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127 USA
45	4-(1-Prop-2-ynyl-1 H-benzoimidazol-2-yl)-furazan-3-ylamine	ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127 USA
46	4-[1-(2-Vinyloxyethyl)-1 H-benzoimidazol-2-yl]-furazan-3-ylamine	ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127 USA


47	4-(1 H-benzoimidazol-2-yl)-furazan-3-ylamine	ChemDiv Inc., P.O. Box 90639, San Diego CA 92169 USA
----	--	---

**Example 48: 2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)-1H-benzimidazol-6-ol**



- 5 The title compound was prepared from 3-fluoro-4-nitrophenol and 7-amino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid t-butyl ester (WO99/14197) by the method of Example 27 Steps 2-5, followed by treatment with TFA in CH<sub>2</sub>Cl<sub>2</sub> to remove BOC protecting group. MS (ES+) m/e 349 [M+H]<sup>+</sup>.


- 10 **Example 49: 1,1-Dimethylethyl 7-[2-(4-amino-furazan-3-yl)-6-fluoro-1H-benzimidazol-1-yl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate**





The title compound was prepared from 2,4-fluoro-nitrobenzene and 7-amino-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid *t*-butyl ester (WO99/14197) by the method of Example 27 Steps 2-5. MS (ES+) *m/e* 451 [M+H]<sup>+</sup>.

5 **Example 50: 4-[1-Ethyl-6-(methyloxy)-1*H*-benzimidazol-2-yl]-furazan-3-ylamine**



**Step 1. 4-Chloro-2-(ethylamino)-nitrobenzene**

- 10 Ethylamine (2 M in THF, 50 mL, 100 mmol) was added to a solution of 2,4-dichloro-nitrobenzene (9.6 g, 50 mmol) and triethylamine (7.6 mL, 55 mmol) in THF (10 mL). The solution was heated to 65 °C for 6 days. The reaction mixture was cooled, poured into H<sub>2</sub>O and extracted with EtOAc. The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), filtered and concentrated. The crude material was purified by column
- 15 chromatography (10-80% EtOAc in hex) to give the title compound (6.41 g, 64%). MS (ES+) *m/e* 201 [M+H]<sup>+</sup>.


**Step 2. 2-(Ethylamino)-4-methoxy-nitrobenzene**

- The product from Step 1 (500 mg, 2.5 mmol) was dissolved in MeOH (5 mL). Sodium
- 20 methoxide (2 mL of a 25% solution in methanol) was added and the mixture was heated to 60 °C for 3 days. The reaction mixture was cooled, poured into H<sub>2</sub>O and extracted with EtOAc. The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), filtered and concentrated to give the title compound (465 mg, 95%). MS (ES+) *m/e* 197 [M+H]<sup>+</sup>.

**Step 3. 4-[1-Ethyl-6-(methoxy)-1H-benzimidazol-2-yl]-furazan-3-ylamine**

The title compound was obtained from the product of Step 2 by the general method of Example 27, Steps 3-5. MS (ES+) m/e 260 [M+H]<sup>+</sup>.


5 **Example 51: 2-(4-amino-furazan-3-yl)-1-ethyl-N,N-dimethyl-1H-benzimidazol-6-amine**

**Step 1. 2-(Ethylamino)-4-dimethylamino-nitrobenzene**

- 10 Dimethylamine hydrochloride (410 mg, 7.5 mmol), triethylamine (1.0 mL, 7.5 mmol) and the product from Example 50, Step 1 (500 mg, 2.5 mmol) were heated to 200 °C in DMF (5 mL) in a microwave reactor for 15 min. The reaction mixture was cooled, poured into H<sub>2</sub>O and extracted with EtOAc. The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), filtered and concentrated. The residue was chromatographed (5-95 % EtOAc
- 15 in hex) to give the title compound (450 mg, 86%). MS (ES+) m/e 210 [M+H]<sup>+</sup>.

**Step 2. 2-(4-Amino-furazan-3-yl)-1-ethyl-N,N-dimethyl-1H-benzimidazol-6-amine**

The title compound was obtained from the product of Step 1 by the general method of Example 27, Steps 3-5. MS (ES+) m/e 274 [M+H]<sup>+</sup>.

**Example 52. 4-[1-Ethyl-6-(phenyloxy)-1H-benzimidazol-2-yl]-furazan-3-ylamine****Step 1. 2-(Ethylamino)-4-fluoro-nitrobenzene**

- 5 The title compound was prepared from 2,4-difluoronitrobenzene and ethylamine by the method of Example 50, Step 1. MS (ES+) m/e 185 [M+H]<sup>+</sup>.

**Step 2. 2-(Ethylamino)-4-phenyloxy-nitrobenzene**

- Phenol (560 mg, 6.0 mmol) in NMP (3 mL) was added to a slurry of sodium hydride  
 10 (60% in oil, 220 mg, 5.5 mmol) in NMP (5 mL) and allowed to stir for 20 min at rt. At this time, the product from Step 1 (900 mg, 5.0 mmol) was added and the mixture was heated to 120 °C overnight. The reaction mixture was cooled, poured into H<sub>2</sub>O and extracted with EtOAc. The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), filtered and concentrated. The residue was chromatographed (0-5 % EtOAc in hex) to  
 15 give the title compound. MS (ES+) m/e 259 [M+H]<sup>+</sup>.

**Step 3. 4-[1-Ethyl-6-(phenyloxy)-1H-benzimidazol-2-yl]-furazan-3-ylamine**

The title compound was obtained from the product of Step 2 by the general method of Example 27, Steps 3-5. MS (ES+) m/e 322 [M+H]<sup>+</sup>.

20 **Pharmacy Examples**

**Tablets**

- |    |                                   |              |
|----|-----------------------------------|--------------|
| a) | Compound of the invention         | 50.0mg       |
|    | Lactose                           | 70.0mg       |
|    | Microcrystalline Cellulose        | 70.0mg       |
| 25 | Cross-linked polyvinylpyrrolidone | 8.0mg        |
|    | Magnesium Stearate                | <u>2.0mg</u> |

Compression weight 200.0mg

The compound of the invention, microcrystalline cellulose, lactose and cross-linked polyvinylpyrrolidone are sieved through a 500 micron sieve and blended in a  
 5 suitable mixer. The magnesium stearate is sieved through a 250 micron sieve and blended with the active blend. The blend is compressed into tablets using suitable punches.

10	b)	Compound of the invention	50.0mg
		Lactose	120.0mg
		Pregelatinised Starch	20.0mg
		Cross-linked polyvinylpyrrolidone	8.0mg
		Magnesium Stearate	<u>2.0mg</u>
		Compression weight	200.0mg

The compound of the invention, lactose and pregelatinised starch are blended  
 15 together and granulated with water. The wet mass is dried and milled. The magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granule. The resultant blend is compressed using suitable tablet punches.

#### Capsules

20	a)	Compound of the invention	50.0mg
		Lactose	148.0mg
		Magnesium Stearate	<u>2.0mg</u>
		Fill weight	200.0mg

The compound of the invention and pregelatinised starch are screened through a  
 25 500 micron mesh sieve, blended together and lubricated with magnesium stearate, (meshed through a 250 micron sieve). The blend is filled into hard gelatine capsules of a suitable size.

	b)	Compound of the invention	50.0mg
		Lactose	132.0mg

Polyvinylpyrrolidone	8.0mg
Cross-linked polyvinylpyrrolidone	8.0mg
Magnesium Stearate	<u>2.0mg</u>
Fill weight	200.0mg

5

The compound of the invention and lactose are blended together and granulated with a solution of polyvinylpyrrolidone. The wet mass is dried and milled. The magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granules. The resultant blend is filled into

10

hard gelatine capsules of a suitable size.

#### Injection Formulation

	% w/v
Compound of the invention	0.10
Water for injections B.P. to	100.00

15

Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability and/or to facilitate solution of the compound of the invention using dilute acid or alkali or by the addition of suitable buffer salts.

Solubilisers, such as cosolvents, may also be added to facilitate solution of the compound of the invention. Antioxidants and metal chelating salts may also be

20

included. The solution is clarified, made up to final volume with water and the pH remeasured and adjusted if necessary, to provide 1mg/ml of the compound of formula (I).

The solution may be packaged for injection, for example by filling and sealing in ampoules, vials or syringes. The ampoules, vials or syringes may be aseptically filled (e.g. the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions) and/or terminally sterilised (e.g. by heating in an autoclave using one of the acceptable cycles). The solution may be packed under an inert atmosphere of nitrogen.

25

Preferably the solution is filled into ampoules, sealed by fusion of the glass and terminally sterilised.

Further sterile formulations are prepared in a similar manner containing 0.05, 0.20 and 0.5% w/v of the compound of the invention, so as to provide respectively 0.5, 2  
5 and 5mg/ml of the compound of the invention.

#### Biological Activity

##### Rho-kinase Activity


Using the test procedure described in the specification the compounds of the examples were found to have a pIC<sub>50</sub> in the range 8.5 to 5.1

##### 10 Msk-1 Activity

The compounds of the examples have a pIC<sub>50</sub> value in the range of 5.0 to 7.7

# Claims


1. A method of treating an Msk-1 and/or ROCK(1 and/or 2)
- 5 mediated disease or condition in a mammal comprising administration of an effective amount of a compounds of the general formula (I)



(I)

and physiologically acceptable salts thereof wherein,


R<sub>1</sub> is a 5, or 6 membered heterocyclic group selected from group a, b, c or d



(a)


10

wherein X<sub>1</sub> is a group selected from N or CR<sub>7</sub> and X<sub>2</sub> is a group selected from O, S or NR<sub>8</sub>;




(b)

- 15 wherein X<sub>3</sub> and X<sub>4</sub> which may be the same or different is a group selected from N or CR<sub>7</sub>;



(c)

wherein  $X_5$  is a group selected from O, S or  $NR_8$  and  $X_8$  is N or  $CR_7$ ;



(d)

- 5 wherein  $X_7$ ,  $X_8$  and  $X_9$  may be the same or different and selected from a group N or  $CR_7$
- $R_2$  and  $R_8$  independently represents hydrogen, hydroxy, aryl, heteroaryl,  $C_{3-7}$ cycloalkyl, heterocyclyl, a group  $YR_9$ ,  $N=R_{10}$ ,  $CONR_{11}R_{12}$ ,  $COCH_2NR_{11}R_{12}$ ,  $NR_{11}COR_{13}$ ,  $SO_2NR_{11}R_{12}$  or  $C_{1-6}$ alkyl [optionally substituted by a group selected from optionally substituted phenyl,  $C_{3-7}$ cycloalkyl, heteroaryl, heterocyclyl, acylamino,  $NH_2$ ,  $R_{16}NH$ ,
- 10  $R_{16}R_{17}N$ ,  $SO_2NR_{11}R_{12}$ ,  $CONR_{11}R_{12}$ ,  $NHCOR_{13}$ ,  $OalkNR_{16}R_{17}$ ,  $SalkNR_{16}R_{17}$  or  $NR_{14}SO_2R_{15}$  group]; or  $R_2$  and  $R_3$  together form a  $C_{2-4}$  alkylene chain.
- $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  independently represent a group selected from hydrogen, halogen, hydroxy,  $R_{16}O$ ,  $R_{16}S(O)_n$ ,  $NH_2$ ,  $R_{16}NH$ ,  $R_{16}R_{17}N$ , nitro, formyl,  $C_{1-4}$ alkanoyl, alkenyl (optionally substituted by optionally substituted phenyl, heterocyclyl, or heteroaryl),
- 15 carboxy, optionally substituted phenyl, heteroaryl, cycloalkyl, cycloalkylalkyl, aryloxy, heteroaryloxy, heterocyclyl,  $CONR_{11}R_{12}$ ,  $NR_{11}COR_{13}$ ,  $SO_2NR_{11}R_{12}$ ,  $NR_{14}SO_2R_{15}$  or  $C_{1-6}$ alkyl [optionally substituted by a group selected from optionally substituted phenyl,  $C_{3-7}$ cycloalkyl, heteroaryl, heterocyclyl,  $NH_2$ ,  $R_{16}NH$ ,  $R_{16}R_{17}N$ , acylamino, hydroxy,  $CONR_{11}R_{12}$ ,  $NR_{11}COR_{13}$ ,  $SO_2NR_{11}R_{12}$ ,  $NR_{14}SO_2R_{15}$ ,  $OalkNR_{16}R_{17}$ , or  $SalkNR_{16}R_{17}$
- 20 group];



Y represents O, NH, NR<sub>9</sub> or S(O)<sub>n</sub>;

R<sub>9</sub> represents aryl, heteroaryl, cycloalkyl, heterocyclyl or C<sub>1-6</sub>alkyl [optionally substituted by a group selected from optionally substituted phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl, heterocyclyl, NH<sub>2</sub>, R<sub>16</sub>NH, R<sub>16</sub>R<sub>17</sub>N, acylamino, hydroxy, CONR<sub>11</sub>R<sub>12</sub>, NR<sub>11</sub>COR<sub>13</sub>,

5 SO<sub>2</sub>NR<sub>11</sub>R<sub>12</sub>, NR<sub>14</sub>SO<sub>2</sub>R<sub>15</sub>, OalkNR<sub>16</sub>R<sub>17</sub>, or SalkNR<sub>16</sub>R<sub>17</sub> group];

R<sub>10</sub> represents an alkylidene group which may be substituted by an aryl, heteroaryl, heterocyclyl or cycloalkyl group or R<sub>10</sub> represents a cycloalkylidene or heterocycloalkylidene group.

R<sub>11</sub> and R<sub>12</sub> independently represent hydrogen, aryl, heteroaryl, cycloalkyl or C<sub>1-6</sub>alkyl [optionally substituted by a group selected from optionally substituted phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl, heterocyclyl, NH<sub>2</sub>, R<sub>16</sub>NH, R<sub>16</sub>R<sub>17</sub>N, or acylamino group] or R<sub>11</sub> and R<sub>12</sub> together with the nitrogen atom to which they are attached form a 4-7 heterocyclic ring which may be saturated or unsaturated and optionally contains another heteroatom selected from O, N or S(O)<sub>n</sub>;

15 R<sub>13</sub> and R<sub>15</sub> independently represent aryl, heteroaryl, heterocyclyl, cycloalkyl or C<sub>1-6</sub>alkyl [optionally substituted by a group selected from optionally substituted phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl, heterocyclyl, NH<sub>2</sub>, R<sub>16</sub>NH, R<sub>16</sub>R<sub>17</sub>N, or acylamino group] or the group NR<sub>11</sub>R<sub>12</sub> wherein R<sub>11</sub> and R<sub>12</sub> have the meanings defined above;

R<sub>14</sub> represents hydrogen, aryl, heteroaryl, heterocyclyl, cycloalkyl or C<sub>1-6</sub>alkyl [optionally substituted by a group selected from optionally substituted phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl, heterocyclyl, NH<sub>2</sub>, R<sub>16</sub>NH, R<sub>16</sub>R<sub>17</sub>N, or acylamino group];


R<sub>16</sub> and R<sub>17</sub> independently represent a group selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

25 Alk is a C<sub>2-4</sub> straight or branched alkylene chain

n is zero, 1 or 2.


2. A method as claimed in claim 1 wherein  $R_1$  is the group (c) in which  $X_5$  is oxygen and  $X_6$  is nitrogen.
3. A method as claimed in claim 1 or claim 2 wherein  $R_2$  represents hydrogen,  $C_{1-6}$ alkyl alkenyl, alkynyl,  $C_{3-7}$  cycloalkyl,  $C_3$ - $C_{3-7}$ cycloalkylmethyl, phenyl or phenyl substituted by (halogen or aminomethyl), heteroaryl, alkyl substituted by (amino,  $R_{16}NH$  or  $R_{16}R_{17}N$ ), 4-7 membered heterocyclyl group, alkyl substituted by a 4-7 membered heterocyclyl group, a 6 membered heteroaryl group fused to a partially saturated carbocyclic ring, alkyl substituted by optionally substituted phenyl, alkyl substituted by alkenyloxy, or alkyl substituted by trifluoromethyl.
- 10 4. A method as claimed in any of claims 1 to 3 wherein  $R_2$  is a group selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, allyl, propargyl, cyclopropyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, phenyl or phenyl (substituted by chlorine), pyridyl, 2-aminoethyl, 2-dimethylaminoethyl, 2-amino-1-methylethyl, 2-dimethylamino-1-methylethyl, 4-piperidiny, t-butyloxycarbonyl-piperidinyl, and 1-ethylpyrrolidin-2-yl-methyl, 3-(4-methyl piperazinyl-1-yl)propyl, 1,2,3,4-tetrahydroisoquinolin-7-yl and the t-butyloxycarbonyl derivative thereof, 1-phenylethyl, 2-vinyloxyethyl, or 2,2,2-trifluoroethyl.
5. A method as claimed in any of claims 1 to 4 wherein  $R_3$  is hydrogen or  $R_3$  and  $R_2$  together represent propylene chain.
- 20 6. A method as claimed in any of claims 1 to 5 wherein  $R_4$  is a group selected from hydrogen, chlorine, fluorine, dimethylamino, phenoxy or hydroxy.
7. A method as claimed in any of claims 1 to 6 wherein  $R_5$  is a group selected from hydrogen, methyl, bromine, chlorine, ethoxy, formyl, acetyl, hydroxymethyl or hydroxy.
8. A method as claimed in any of claims 1 to 7 wherein  $R_6$  is a group selected from hydrogen, ethylamino or nitro.
- 25 9. A method as claimed in any of claims 1 to 8 wherein the compound of formula (1) is a compound selected from any of examples 1 to 52.

10. A pharmaceutical formulation comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.
11. The use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt thereof for the manufacture of a medicament for inhibiting the effects of the kinases Msk-1 and/or ROCK(1 and2).
12. A compound selected from any of examples 1 to 40 and 48 to 52
13. A process for preparing compounds of formula (I) which comprises:-
- a) A process for preparing compounds of formula (I) wherein R<sub>1</sub> is a group (a), (c) and (d) may be prepared by reacting the diamine (II)




(II)


wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> have the meanings defined in (I) with the appropriate compound of formula (III), (IV) or (V)



(III)



(IV)




(V)

wherein Z is hydrogen, halogen e.g. Cl, Br or I, hydroxy or C<sub>1-4</sub>alkoxy, Ra is hydrogen or a nitrogen protecting group such as an alkoxycarbonyloxy or benzyloxycarbonyloxy group and each of X<sub>1</sub>, X<sub>2</sub>, X<sub>5</sub>, X<sub>6</sub>, X<sub>7</sub>, X<sub>8</sub> and X<sub>9</sub> have the meanings as defined in formula

(I) or is a group available thereto, followed when required by removal of the nitrogen protecting group Ra using conventional methods.

b) A process for preparing compounds of formula (I) wherein R<sub>1</sub> is the group (b) by reducing of the corresponding nitro derivative (VI)




(VI)

5

wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, X<sub>3</sub> and X<sub>4</sub> have the meanings defined in formula (I).

c) a process for preparing compounds of formula (I) wherein R<sub>1</sub> is the group (c) and X<sub>5</sub> is oxygen and X<sub>6</sub> is nitrogen by reacting the nitrile (VII)




(VII)

10 wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> have the meanings defined in formula (I) with hydrochloric acid and sodium nitrite in a solvent and treatment of the product thus formed with a base and hydroxylamine.

d) A process for preparing compounds of formula (I) wherein R<sub>1</sub> is the group (c) and X<sub>5</sub> is oxygen and X<sub>6</sub> is nitrogen by reacting the diamine (II) with 5-methyl-[1,4,5]

15 oxadiazolo [3,4-d] pyrimidin-7-ol in glacial acetic acid.

e) a process for preparing compounds of formula (I) wherein R<sub>1</sub> represent the group (c) wherein X<sub>5</sub> is NH and X<sub>6</sub> is CH by reacting compound (VIII)



wherein  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  have the meanings defined in formula (I) with hydrazine.

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
WO 03/080125 A3(51) International Patent Classification<sup>7</sup>: A61K 31/4184,  
31/4245, A61P 25/00, C07D 413/04, 413/14, 403/04,  
471/06 // (C07D 471/06, 235/00, 221/00)[GB/GB]; GlaxoSmithKline, New Frontiers Science Park  
South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(21) International Application Number: PCT/GB03/01210

(74) Agent: GIDDINGS, Peter, John; GlaxoSmithKline, 980  
Great West Road CN925.1, Brentford, Middlesex TW8  
9GS (GB).

(22) International Filing Date: 21 March 2003 (21.03.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:  
0206861.7 22 March 2002 (22.03.2002) GB(71) Applicant (*for all designated States except US*): GLAXO  
GROUP LIMITED [GB/GB]; Glaxo Wellcome House,  
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and



(75) Inventors/Applicants (*for US only*): ALBERTI,  
Michael, John [US/US]; GlaxoSmithKline, Five Moore  
Drive, Research Triangle Park, NC 27709 (US). GAR-  
LAND, Stephen [GB/GB]; GlaxoSmithKline, New  
Frontiers Science Park South, Third Avenue, Harlow, Es-  
sex CM19 5AW (GB). JUNG, David, Kendall [US/US];  
GlaxoSmithKline, Five Moore Drive, Research Triangle  
Park, NC 27709 (US). VEAL, James, Marvin [US/US];  
c/o GlaxoSmithKline, Five Moore Drive, Research Tri-  
angle Park, NC 27709 (US). WITHERINGTON, Jason(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

[Continued on next page]

(54) Title: BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS



(57) Abstract: A method of treating an Msk-1 and/or ROCK(1 and 2) mediated disease or condition in a mammal comprising administration of an effective amount of a compounds of the formula (I) and physiologically acceptable salts thereof wherein, R<sub>1</sub> is a 5, or 6 membered heterocyclic group selected from group a, b, c or d wherein X<sub>1</sub> is a group selected from N or CR<sub>7</sub> and X<sub>2</sub> is a group selected from O, S or NR<sub>8</sub>; X<sub>3</sub> and X<sub>4</sub> which may be the same or different is a group selected from N or CR<sub>7</sub>; X<sub>5</sub> is a group selected from O, S or NR<sub>8</sub> and X<sub>6</sub> is N or CR<sub>7</sub>; X<sub>7</sub>, X<sub>8</sub> and X<sub>9</sub> may be the same or different and selected from a group N or CR<sub>7</sub>, pharmaceutical compositions, novel compounds and processes for their preparation.



**(88) Date of publication of the international search report:**  
6 November 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/01210

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4184 A61K31/4245 A61P25/00 C07D413/04 C07D413/14  
 C07D403/04 C07D471/06  
 //(C07D471/06,235:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VIJAYENDER REDDY K ET AL: "Synthesis of 2-(2-amino-3-pyridyl)benzimidazoles" IDIAN JOURNAL OF CHEMISTRY, SECTION B, vol. 23b, no. 9, September 1984 (1984-09), pages 866-867, XP008018057 the whole document	10
X	DATABASE CHEMCATS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002243488 accession no. STN Database accession no. 2000:1083251 RN 296243-41-9 & "Screening Collection (Catalog)" 28 March 2000 (2000-03-28), , ZELINSKY INSTITUTE , WILMINGTON, DE, US Order Number A1924/0080922 ----- -/-	12

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

5 June 2003

Date of mailing of the international search report

15. 09. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Allard, M.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/01210

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CHEMCATS [Online]            CHEMICAL ABSTRACTS SERVICE, COLUMBUS,            OHIO, US;            XP002243489 accession no. STN            Database accession no. 2001:1430363            RN 293760-29-9            &amp; "Screening Collection (Catalog)"            28 March 2000 (2000-03-28), , ZELINSKY            INSTITUTE , WILMINGTON, DE, US            Order Number A2090/0087896</p> <p>-----</p>	12
X	<p>DATABASE CHEMCATS [Online]            CHEMICAL ABSTRACTS SERVICE, COLUMBUS,            OHIO, US;            XP002243490 accession no. STN            Database accession no. 2002:1417269            RN 384860-37-1            &amp; "LaboTest Stock (Catalog)"            2 January 2002 (2002-01-02), , LABOTEST ,            NIEDERSCHONA, DE            Order Number LT01184225</p> <p>-----</p>	12
X	<p>DATABASE CHEMCATS [Online]            CHEMICAL ABSTRACTS SERVICE, COLUMBUS,            OHIO, US;            XP002243491 accession no. STN            Database accession no. 2002:597067            RN 332026-41-2            &amp; "ChemBridge Product List (Catalog)"            17 January 2002 (2002-01-17), , CHEMBRIDGE            CORPORATION , SAN DIEGO, CA, US            Order Number 6057908</p> <p>-----</p>	12
X	<p>DATABASE CROSSFIRE BEILSTEIN            Beilstein Institut zur Förderung der            Chemischen Wissenschaften, Frankfurt am            Main, DE;            XP002243492            Beilstein Registry Number 8907321            &amp; ZH. ORG. KHIM. (RU),            vol. 37, no. 5, 2001, pages 755-758,</p> <p>-----</p>	12
A	<p>WO 99 10325 A (GLAXO GROUP LIMITED)            4 March 1999 (1999-03-04)            the whole document</p> <p>-----</p>	1
A	<p>US 4 859 684 A (RAEYMAEKERS A H M ET AL)            22 August 1989 (1989-08-22)            example 53</p> <p>-----</p>	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/01210

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FADDA A A ET AL: "Activated nitriles in heterocyclic synthesis: a novel synthesis of polyfunctionally substituted pyridine derivatives"  MONATSHFTE FÜR CHEMIE,  vol. 130, no. 12, 1999, pages 1487-1492,  XP002243482  compounds 5b, 5k</p> <p>-----</p>	
A	<p>YAMAGUCHI Y ET AL: "Structure and properties of ethyl (2-benzimidazolyl)cyanoacetimidate"  JOURNAL OF HETEROCYCLIC CHEMISTRY,  vol. 36, no. 4, 1999, pages 841-847,  XP002243483  compound 29</p> <p>-----</p>	
A	<p>OKAMOTO Y ET AL: "A novel synthesis of pyrido[2,3-b][1,5]benzodiazepines"  JOURNAL OF HETEROCYCLIC CHEMISTRY,  vol. 31, no. 1, 1994, pages 49-52,  XP002243484  compound 3c</p> <p>-----</p>	
A	<p>TAKAGI K ET AL: "Synthesis of pyrimidino[4,5-b][1,5]benzodiazepin-2-ones and pyrimidino[1,6-a]benzimidazol-1-ones from 4-[(ethoxycarbonyl)amino]-1H-1,5-benzodiazepine-3-carbonitrile via 4-(2-aminoanilino)pyrimidin-2(1H)-one-5-carbonitriles"  JOURNAL OF HETEROCYCLIC CHEMISTRY,  vol. 23, no. 5, 1986, pages 1443-1449,  XP002243485  compound 11</p> <p>-----</p>	
A	<p>KREUTZBERGER A ET AL: "5-Substituierte 4-Aminopyrimidine durch Aminomethinylierung von Acetonitrilen"  LIEBIGS ANNALEN DER CHEMIE, no. 4, 1977,  pages 537-544, XP002243486  compound 6i</p> <p>-----</p>	
A	<p>ZAHARAN M A ET AL: "Some reactions with ketene dithioacetals. Part I. Synthesis of antimicrobial pyrazolo[1,5-a]pyrimidines via the reaction of ketene dithioacetals and 5-aminopyrazoles"  IL FARMACO,  vol. 56, no. 4, 1 April 2001 (2001-04-01),  pages 277-283, XP002243487  compounds 9a-d</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 03/01210

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 1-9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**see additional sheet**

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
**1-12, 13 (partly)**

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-12, 13 (partly)

Medical use of benzimidazoles and certain specific benzimidazoles

---

2. claim: 13 (partly)

Preparation of known benzimidazoles by cycloaddition of benzenediamines (process a)

---

3. claim: 13 (partly)

Preparation of known 2-(amino-heteroaryl)-benzimidazoles by reduction of 2-(nitro-heteroaryl)-benzimidazoles (process b)

---

4. claim: 13 (partly)

Preparation of known 2-oxadiazolyl-benzimidazoles (processes c and d)

---

5. claim: 13 (partly)

Preparation of known 2-pyrazolyl-benzimidazoles (process e)

---

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/01210

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9910325	A	04-03-1999	AU 9158498 A	16-03-1999
			WO 9910325 A1	04-03-1999
			EP 1003721 A1	31-05-2000
			JP 2002514228 T	14-05-2002
			US 6268391 B1	31-07-2001
			ZA 9807037 A	07-02-2000
-----				
US 4859684	A	22-08-1989	CS 9103826 A3	15-04-1992
			AT 83478 T	15-01-1993
			AU 595064 B2	22-03-1990
			AU 7838587 A	14-04-1988
			BG 61321 B2	30-05-1997
			BR 1101052 A3	28-03-2000
			CA 1323366 C	19-10-1993
			CN 87106423 A ,B	20-04-1988
			CY 1803 A	09-09-1987
			DE 3783107 D1	28-01-1993
			DE 3783107 T2	22-04-1993
			DK 479487 A	16-03-1988
			EP 0260744 A2	23-03-1988
			ES 2053524 T3	01-08-1994
			FI 873977 A ,B,	16-03-1988
			GR 3006841 T3	30-06-1993
			HK 123694 A	18-11-1994
			HU 45051 A2	30-05-1988
			IE 60514 B1	27-07-1994
			IL 83892 A	21-11-1991
			JP 1085975 A	30-03-1989
			JP 1875175 C	26-09-1994
			JP 5087071 B	15-12-1993
			KR 9614353 B1	15-10-1996
			KR 9615004 B1	23-10-1996
			LT 2087 R3	15-07-1993
			LV 5029 A3	10-06-1993
			LV 5770 A4	20-12-1996
			NO 873840 A ,B,	16-03-1988
			NZ 221729 A	27-07-1989
			PH 25022 A	28-01-1991
			PT 85692 A ,B	01-10-1987
			SG 118994 G	28-04-1995
			SU 1662350 A3	07-07-1991
			ZA 8706881 A	26-04-1989
-----				

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**